<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prevention of chemotherapy-induced nausea and vomiting in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prevention of chemotherapy-induced nausea and vomiting in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prevention of chemotherapy-induced nausea and vomiting in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul J Hesketh, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reed E Drews, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 05, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Few side effects of cancer treatment are more feared by patients than nausea and vomiting. Although nausea and emesis (vomiting and/or retching) can result from surgery or radiation therapy, chemotherapy-induced nausea and vomiting (CINV) is potentially the most severe and most distressing. Significant progress has been made, but CINV remains an important adverse effect of treatment.</p><p>Three distinct types of CINV have been defined, with important implications for both prevention and management:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute emesis, which most commonly begins within one to two hours of chemotherapy and usually peaks in four to six hours</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Delayed emesis, occurring more than 24 hours after chemotherapy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anticipatory emesis, occurring prior to treatment as a conditioned response in patients who have developed significant nausea and vomiting during previous cycles of chemotherapy</p><p></p><p>The objective of antiemetic therapy is the complete prevention of CINV, and this should be achievable in the majority of patients receiving chemotherapy, even with highly emetic agents.</p><p>Prevention of CINV in adult patients receiving cancer chemotherapy will be reviewed here. The management of breakthrough and poorly controlled CINV and the pathophysiology of CINV are discussed separately, as are the characteristics of antiemetic drugs, and nausea and vomiting associated with radiation therapy and opioid analgesics. (See  <a class="medical medical_review" href="/z/d/html/134925.html" rel="external">"Management of poorly controlled or breakthrough chemotherapy-induced nausea and vomiting in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1150.html" rel="external">"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting"</a> and  <a class="medical medical_review" href="/z/d/html/2538.html" rel="external">"Characteristics of antiemetic drugs"</a> and  <a class="medical medical_review" href="/z/d/html/7052.html" rel="external">"Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment"</a> and  <a class="medical medical_review" href="/z/d/html/2800.html" rel="external">"Prevention and management of side effects in patients receiving opioids for chronic pain", section on 'Nausea and vomiting'</a>.)</p><p class="headingAnchor" id="H2420355536"><span class="h1">OVERVIEW OF THE APPROACH TO PROPHYLAXIS</span></p><p class="headingAnchor" id="H3323525354"><span class="h2">Estimating the risk of nausea and vomiting</span><span class="headingEndMark"> — </span>The most important factor determining the likelihood of acute or delayed emesis developing during chemotherapy is the intrinsic emetogenicity of the particular agent. Although other factors may be important, such as patient age, sex, and history of alcohol consumption, these factors are not currently used to select the antiemetic strategy. (See  <a class="medical medical_review" href="/z/d/html/1150.html" rel="external">"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting", section on 'Chemotherapy agent'</a> and  <a class="medical medical_review" href="/z/d/html/1150.html" rel="external">"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting", section on 'Prediction models'</a>.)</p><p>The management of CINV has been greatly facilitated by the development of classification schemes that reflect the likelihood of emesis developing following treatment with particular agents. A 1997 classification scheme gained broad acceptance and was utilized as the basis for treatment recommendations by guideline panels [<a href="#rid1">1</a>]. A modification of this schema was proposed at the 2004 Perugia Antiemetic Consensus Guideline meeting [<a href="#rid2">2</a>] and is still relevant, although many more chemotherapy agents are now available. Chemotherapy agents were divided into four categories based upon the risk of emesis in the absence of antiemetic prophylaxis:</p><p class="bulletIndent1"><span class="glyph">●</span>Highly emetic – &gt;90 percent risk of emesis</p><p class="bulletIndent1"><span class="glyph">●</span>Moderately emetic – &gt;30 to 90 percent risk of emesis</p><p class="bulletIndent1"><span class="glyph">●</span>Low emetogenicity – 10 to 30 percent risk of emesis</p><p class="bulletIndent1"><span class="glyph">●</span>Minimally emetic – &lt;10 percent risk of emesis</p><p></p><p>This drug classification schema is utilized in both the updated antiemetic guidelines of the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmascc.org%2Fresources%2Fmascc-guidelines%2F&amp;token=795%2BxPqISNblxEq%2B8WXBBjoU8Peh%2FAysEk%2FPCZ98NtpEW3K8qd7SLaghSimhgt0C&amp;TOPIC_ID=1151" target="_blank">Multinational Association of Supportive Care in Cancer (MASCC)/European Society for Medical Oncology (ESMO)</a> and the American Society of Clinical Oncology (ASCO) [<a href="#rid3">3-8</a>]. A classification of specific agents according to their emetogenic potential is provided separately for parenteral and oral agents  (<a class="graphic graphic_table graphicRef58756" href="/z/d/graphic/58756.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef65923" href="/z/d/graphic/65923.html" rel="external">table 2</a>).</p><p>For combination regimens, the emetic level is determined by identifying the most emetic agent in the combination and then assessing the relative contribution of the other agents. As an example, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a> are both moderately emetogenic agents, but when given together, the regimen is highly emetic [<a href="#rid1">1</a>]. In updated antiemetic guidelines from ASCO, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmascc.org%2Fresources%2Fmascc-guidelines%2F&amp;token=795%2BxPqISNblxEq%2B8WXBBjoU8Peh%2FAysEk%2FPCZ98NtpEW3K8qd7SLaghSimhgt0C&amp;TOPIC_ID=1151" target="_blank">MASCC/ESMO</a>, and the National Comprehensive Cancer Network (NCCN) [<a href="#rid8">8</a>], combined anthracycline and cyclophosphamide (AC) regimens have been reclassified as highly emetic [<a href="#rid3">3,5-8</a>]. It should be noted that the studies defining the AC regimens as highly emetogenic were conducted almost exclusively in women with breast cancer. It is unclear whether AC used as a component of combination regimens in other diseases with more diverse populations (eg, doxorubicin plus cyclophosphamide, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> [CHOP] in non-Hodgkin lymphoma) is also highly emetic. For example, an open-label, single-arm trial in patients with non-Hodgkin lymphoma (75 percent receiving CHOP + <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>) evaluated a single dose of <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> (0.25 mg intravenously) prior to chemotherapy, achieving an overall complete response rate of 86 percent [<a href="#rid9">9</a>]. Many clinicians consider CHOP and related regimens to be moderately rather than highly emetogenic. (See <a class="local">'Palonosetron'</a> below.)</p><p class="headingAnchor" id="H3190319902"><span class="h2">Choosing the prophylactic strategy</span><span class="headingEndMark"> — </span>The three categories of drugs with the highest therapeutic index for the management of CINV are the type three 5-hydroxytryptamine (5-HT3) receptor antagonists, the neurokinin-1 receptor (NK1R) antagonists, and glucocorticoids (especially <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>). In addition, more recent data have demonstrated substantial antiemetic activity for the antipsychotic medication <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> when used in combination with other antiemetics. (See <a class="local">'5-HT3 receptor antagonists'</a> below and <a class="local">'Neurokinin-1 receptor antagonists'</a> below and <a class="local">'Glucocorticoids'</a> below and <a class="local">'Olanzapine'</a> below.)</p><p>These agents are used alone and in specific combinations, depending on the emetogenicity of the specific chemotherapy regimen being administered and its tendency to produce not only acute but also delayed emesis. In general, most of the regimens that are associated with delayed emesis are those that are highly emetogenic, although there are some moderately emetogenic agents that also fit into this category.</p><p>An important point is that virtually all of the clinical trials evaluating CINV have focused on intravenously delivered chemotherapy. Therefore, evidenced-based guidelines for antiemetic prophylaxis with oral chemotherapy agents are not currently possible. The following recommendations, unless indicated otherwise, pertain to intravenously administered chemotherapy agents. Management of antiemetics for patients receiving oral chemotherapy is discussed below. (See <a class="local">'Oral chemotherapy'</a> below.)</p><p class="headingAnchor" id="H3902069707"><span class="h2">Recommendations for specific groups</span><span class="headingEndMark"> — </span>Guidelines for antiemetic therapy for intravenously administered chemotherapy according to the estimated risk of CINV are available from ASCO and NCCN [<a href="#rid8">8</a>] and in a year 2016 update of recommendations from <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmascc.org%2Fresources%2Fmascc-guidelines%2F&amp;token=795%2BxPqISNblxEq%2B8WXBBjoU8Peh%2FAysEk%2FPCZ98NtpEW3K8qd7SLaghSimhgt0C&amp;TOPIC_ID=1151" target="_blank">MASCC/ESMO</a> [<a href="#rid5">5-8</a>]. Our approach to prophylaxis, which largely parallels recommendations from MASCC/ESMO and ASCO, is summarized in the following sections and outlined in the accompanying table  (<a class="graphic graphic_table graphicRef72865" href="/z/d/graphic/72865.html" rel="external">table 3</a>).</p><p class="headingAnchor" id="H2873481867"><span class="h3">Highly emetogenic chemotherapy</span></p><p class="headingAnchor" id="H3606285232"><span class="h4">Cisplatin and other highly emetogenic single agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Day 1</strong> – We recommend antiemetic therapy with a combination of an NK1R antagonist, a 5-HT3 receptor antagonist, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, and <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>. (See <a class="local">'5-HT3 receptor antagonists'</a> below and <a class="local">'Neurokinin-1 receptor antagonists'</a> below and <a class="local">'Combination with a 5-HT3 antagonist'</a> below and <a class="local">'Olanzapine'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Days 2 to 4</strong> – We recommend continuing <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (days 2 to 4) and continuing <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> (days 2 to 4).</p><p></p><p class="bulletIndent1">If <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> is used on day 1, we recommend continuing aprepitant on days 2 and 3  (<a class="graphic graphic_table graphicRef72865" href="/z/d/graphic/72865.html" rel="external">table 3</a>). All other NK1R antagonists (ie, <a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">fosaprepitant</a>, <a class="drug drug_general" data-topicid="103785" href="/z/d/drug information/103785.html" rel="external">rolapitant</a>, netupitant) are administered on day 1 only.</p><p></p><p class="headingAnchor" id="H3546073978"><span class="h4">Anthracycline combined with cyclophosphamide</span></p><p class="headingAnchor" id="H2298640625"><span class="h5">Breast cancer</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Day 1</strong> – We recommend a combination of an NK1R antagonist, a 5-HT3 receptor antagonist, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, and <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Days 2 to 4</strong> – We recommend continuing <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> on days 2 to 4. We suggest not using <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> on days 2 to 4 because of the limited data supporting dexamethasone beyond day 1 when an NK1R antagonist is used with AC. (See <a class="local">'NK1R antagonist plus dexamethasone and 5-HT3 antagonist'</a> below.)</p><p></p><p class="bulletIndent1">If <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> is used on day 1, we recommend continuing aprepitant on days 2 and 3. All other NK1R antagonists are administered on day 1 only.</p><p></p><p class="headingAnchor" id="H833881859"><span class="h5">Other diseases</span><span class="headingEndMark"> — </span>For non-breast cancer populations (eg, non-Hodgkin lymphoma) receiving combination AC with treatment regimens incorporating corticosteroids, the use of the 5-HT3 antagonist <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> without the use of an NK1R antagonist or <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> is an acceptable option. (See <a class="local">'Palonosetron'</a> below.)</p><p class="headingAnchor" id="H4061881691"><span class="h3">Moderately emetogenic chemotherapy</span></p><p class="headingAnchor" id="H540473364"><span class="h4">Carboplatin-based regimens</span><span class="headingEndMark"> — </span>The NCCN classifies <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> doses of area under the curve of concentration X time (AUC) 4 or higher as highly emetogenic, but both ASCO and MASCC classify all doses of carboplatin as being moderately emetogenic [<a href="#rid5">5,7,8</a>]. However, despite the classification of carboplatin-containing regimens as moderately emetogenic at many institutions, the benefit of adding an NK1R antagonist on day 1 has been shown in many studies; for most patients, prophylaxis for delayed emesis beyond day 1 is not needed.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Day 1</strong> – We recommend the combination of an NK1R antagonist, a 5-HT3 receptor antagonist, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> on day 1.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No additional prophylaxis beyond day 1 for delayed emesis is recommended. (See <a class="local">'Moderate-risk regimens'</a> below.)</p><p></p><p class="headingAnchor" id="H318780863"><span class="h4">Non-carboplatin-based regimens</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Day 1</strong> – We recommend the combination of a 5-HT3 receptor antagonist plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> on day 1.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Days 2 to 3</strong> – To prevent delayed emesis if the regimen contains agents with known potential to induce delayed emesis (eg, <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>), we suggest single-agent treatment with <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> on days 2 and 3. If a first-generation 5-HT3 receptor antagonist is used rather than <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> on day 1, then treatment with a first-generation 5-HT3 receptor antagonist alone on days 2 and 3 is a reasonable alternative. If palonosetron is used on day 1, no additional prophylaxis beyond day 1 is needed for most patients. (See <a class="local">'Moderate-risk regimens'</a> below and <a class="local">'Dexamethasone duration in patients receiving moderately emetogenic chemotherapy'</a> below.)</p><p></p><p class="headingAnchor" id="H1470327107"><span class="h3">Low emetogenic chemotherapy</span></p><p class="bulletIndent1"><span class="glyph">●</span>For patients receiving low-emetic-risk agents, we suggest treatment with <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (4 to 8 mg, oral or IV) as a single agent or a 5-HT3 receptor antagonist. Other alternative approaches for patients in whom glucocorticoid use is contraindicated or undesirable (such as with the use of long-term weekly chemotherapy) are a single oral or IV dose of a drug such as <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">prochlorperazine</a> (5 to 10 mg, oral or IV) [<a href="#rid8">8</a>], or <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> (10 mg, oral or IV). This patient population generally does not require prophylaxis against delayed emesis. (See <a class="local">'Glucocorticoids'</a> below.)</p><p></p><p class="headingAnchor" id="H2688092008"><span class="h3">Minimally emetogenic chemotherapy</span></p><p class="bulletIndent1"><span class="glyph">●</span>For most patients receiving chemotherapy agents with a minimal risk of causing emesis, we suggest that antiemetic therapy <strong>not</strong> be routinely administered to prevent either acute or delayed CINV. Prophylactic antiemetics (<a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> 4 to 8 mg, oral or IV; <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">prochlorperazine</a> 5 or 10 mg, oral or IV; or <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> 10 mg, oral or IV) may be administered to patients who have had emesis with prior low-risk regimens, or on an "as needed" basis. (See  <a class="medical medical_review" href="/z/d/html/1150.html" rel="external">"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting", section on 'Chemotherapy agent'</a>.)</p><p></p><p class="headingAnchor" id="H3920419696"><span class="h3">Immune checkpoint inhibitor immunotherapy</span></p><p class="bulletIndent1"><span class="glyph">●</span>For adult patients, the addition of an immune checkpoint inhibitor (ICI) to cytotoxic chemotherapy does not change the guideline recommendation for an antiemetic regimen based on the emetogenicity of the agents administered, including the use of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> [<a href="#rid7">7</a>]. Despite a prior guideline that classified <a class="drug drug_general" data-topicid="108314" href="/z/d/drug information/108314.html" rel="external">atezolizumab</a> and <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a> as low-emetic-risk agents [<a href="#rid6">6</a>], the updated 2020 antiemetic guidelines from ASCO classify all ICIs administered either alone or in combination with other checkpoint inhibitors as minimally emetogenic and do not require the use of a prophylactic antiemetic [<a href="#rid7">7</a>]. (See <a class="local">'Patients receiving immune checkpoint inhibitors'</a> below.)</p><p></p><p class="headingAnchor" id="H3200179900"><span class="h3">Anticipatory emesis</span></p><p class="bulletIndent1"><span class="glyph">●</span>The primary approach to the prevention of anticipatory emesis is the prevention of CINV beginning with the initial cycles of chemotherapy. For patients who do develop anticipatory emesis, we suggest behavioral therapy and/or benzodiazepines. (See <a class="local">'Anticipatory emesis'</a> below.)</p><p></p><p class="headingAnchor" id="H132613225"><span class="h3">High-dose chemotherapy</span></p><p class="bulletIndent1"><span class="glyph">●</span>For patients receiving high-dose chemotherapy with hematopoietic cell transplantation, we recommend a combination of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, a 5-HT3 receptor antagonist, and an NK1R antagonist. The most recent ASCO guideline update suggests a four-drug combination of dexamethasone, a 5-HT3 receptor antagonist, an NK1R antagonist, and <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> as an additional option. (See <a class="local">'High-dose chemotherapy regimens'</a> below.)</p><p></p><p class="headingAnchor" id="H1385293232"><span class="h3">Multiday regimens</span></p><p class="bulletIndent1"><span class="glyph">●</span>Adults treated with multiday antineoplastic agents should be offered antiemetics before treatment that are appropriate for the emetic risk of the agent given on each day or the treatment, and for two days after completion of the regimen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients receiving four- or five-consecutive-day <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> regimens, we suggest a daily dose of a first-generation 5-HT3 receptor antagonist, or a single application of a <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">granisetron</a> transdermal patch or <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> on days 1, 3, and 5 plus daily <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, with the addition of <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> (days 1, 2, and 3), <a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">fosaprepitant</a> (day 1), or another NK1R antagonist (eg, netupitant plus palonosetron [NEPA] or <a class="drug drug_general" data-topicid="103785" href="/z/d/drug information/103785.html" rel="external">rolapitant</a>) on day 1. (See <a class="local">'Consecutive-day intravenous therapy with highly emetogenic agents'</a> below.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">ANTIEMETIC EFFICACY OF INDIVIDUAL AGENTS</span><span class="headingEndMark"> — </span>Extensive clinical trials have evaluated the type three 5-hydroxytryptamine (5-HT3) receptor antagonists, the neurokinin-1 receptor (NK1R) antagonists, glucocorticoids, and more recently, <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> in patients with acute and delayed CINV. These trials have focused primarily on patients receiving either highly or moderately emetic, intravenously (IV) administered chemotherapy regimens. Although not all antiemetic regimens have been evaluated with all chemotherapy combinations, it is reasonable to extrapolate data to other chemotherapy regimens of comparable emetogenicity.</p><p class="headingAnchor" id="H4"><span class="h2">5-HT3 receptor antagonists</span><span class="headingEndMark"> — </span>A key advance in the prevention of CINV was the development of selective type three 5-hydroxytryptamine (5-HT3) receptor antagonists, a drug class that has a high therapeutic index for prevention of CINV [<a href="#rid10">10</a>].</p><p>Randomized trials have shown that single-agent 5-HT3 receptor antagonists are more effective than less-specific agents such as high-dose <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> and as effective as the combination of high-dose metoclopramide and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>. When 5-HT3 antagonists are used in combination with dexamethasone, they are more effective than high-dose metoclopramide plus dexamethasone [<a href="#rid11">11-14</a>]. In addition to increased efficacy, these agents are easier to administer and are associated with significantly less serious side effects than the less-specific serotonin inhibitor metoclopramide.</p><p>Six first-generation 5-HT3 receptor antagonists (azasetron [<a href="#rid15">15</a>], <a class="drug drug_general" data-topicid="8592" href="/z/d/drug information/8592.html" rel="external">dolasetron</a>, <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">granisetron</a>, <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a>, ramosetron, and tropisetron) and one second-generation agent (<a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a>) are approved for use with varying regional availability; azasetron, ramosetron, and tropisetron are not available in the United States. An orally disintegrating formulation of ondansetron also is available, which disperses rapidly when placed on the tongue and does not need to be swallowed with water [<a href="#rid16">16</a>]. This formulation may be particularly useful for patients with dysphagia or anorexia. A granisetron transdermal system is also available, as is an extended-release subcutaneous formulation of granisetron (Sustol), which was approved by the US Food and Drug Administration (FDA) in August 2016 for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, or combination anthracycline and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> chemotherapy regimens. (See <a class="local">'Granisetron transdermal patch'</a> below.)</p><p class="headingAnchor" id="H5"><span class="h3">First-generation agents</span><span class="headingEndMark"> — </span>A large number of randomized trials have clarified the properties of the first-generation 5-HT3 receptor antagonists. Key findings include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The first-generation 5-HT3 receptor antagonists all appear equally effective at preventing CINV at the recommended doses. A meta-analysis has shown no clear advantage for either <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> or <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">granisetron</a> in the prophylaxis of acute or delayed emesis [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is a plateau in therapeutic efficacy at a definable dose level for each drug, and further dose escalation does not improve outcome [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A single dose of a 5-HT3 receptor antagonist prior to chemotherapy is therapeutically equivalent to a multiple-dose schedule for control of acute nausea and emesis [<a href="#rid19">19-23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The efficacy of 5-HT3 receptor antagonists is significantly improved when they are combined with glucocorticoids. (See <a class="local">'Glucocorticoids'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oral formulations of these agents are as effective as IV formulations [<a href="#rid18">18,24,25</a>].</p><p></p><p class="headingAnchor" id="H2662553"><span class="h4">Cardiac issues</span><span class="headingEndMark"> — </span>Electrocardiogram (ECG) interval changes are a class effect of the first-generation 5-HT3 antagonists, including <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a>, <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">granisetron</a>, and <a class="drug drug_general" data-topicid="8592" href="/z/d/drug information/8592.html" rel="external">dolasetron</a>, although they have not been reported with transdermal granisetron or extended-release subcutaneous granisetron [<a href="#rid26">26,27</a>]. (See <a class="local">'Granisetron transdermal patch'</a> below.)</p><p>ECG interval changes appear to be most prominent one to two hours after a dose of these agents, are mostly small and clinically insignificant, and return to baseline within 24 hours [<a href="#rid28">28-30</a>]. However, potentially fatal cardiac arrhythmias, including torsade de pointes (TdP), have been reported in association with QTc prolongation [<a href="#rid28">28,30-32</a>].</p><p>In addition to ECG interval changes, myocardial ischemia has been reported in patients treated with <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a>; coronary artery spasm appears to be the most common underlying cause [<a href="#rid33">33</a>].</p><p>The following sections describe the warnings/precautions regarding cardiotoxicity of these agents from the FDA.</p><p class="headingAnchor" id="H13889233"><span class="h5">Dolasetron</span><span class="headingEndMark"> — </span>Due to the risk of QTc prolongation from increased drug exposure, the injection form of <a class="drug drug_general" data-topicid="8592" href="/z/d/drug information/8592.html" rel="external">dolasetron</a> is contraindicated for prophylaxis of CINV in both children and adults [<a href="#rid34">34</a>]. The risk of developing an abnormal heart rhythm with oral dolasetron is less than that seen with the injection form. However, there is still a potential risk.</p><p>The FDA recommends the following precautions in patients receiving <strong>oral</strong> <a class="drug drug_general" data-topicid="8592" href="/z/d/drug information/8592.html" rel="external">dolasetron</a> [<a href="#rid34">34</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Potassium and magnesium levels should be assessed and, if abnormal, corrected before initiation of treatment with <a class="drug drug_general" data-topicid="8592" href="/z/d/drug information/8592.html" rel="external">dolasetron</a>. These electrolytes should be monitored after administration, as clinically indicated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use electrocardiographic monitoring in patients with heart failure, a slow heart rate, or underlying cardiac disease, in older adults, and in patients with renal impairment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of <a class="drug drug_general" data-topicid="8592" href="/z/d/drug information/8592.html" rel="external">dolasetron</a> should be avoided in patients with congenital long QT syndrome  (<a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drugs known to prolong the PR (eg, <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>) or QRS interval (eg, <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a>, <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>) should be avoided in patients taking <a class="drug drug_general" data-topicid="8592" href="/z/d/drug information/8592.html" rel="external">dolasetron</a>.</p><p></p><p>Because of these risks, <a class="drug drug_general" data-topicid="8592" href="/z/d/drug information/8592.html" rel="external">dolasetron</a> (both oral and IV) has been removed from the market in Canada, but it remains available elsewhere.</p><p class="headingAnchor" id="H13889240"><span class="h5">Ondansetron</span><span class="headingEndMark"> — </span>The FDA has issued a warning about QTc prolongation and potentially fatal cardiac arrhythmias in patients treated with <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> [<a href="#rid32">32</a>]. QT prolongation occurs in a dose-dependent manner and, specifically, at a single IV dose of 32 mg. QT interval prolongation is expected to be greater with a faster rate of infusion and larger doses for IV administration.</p><p>Revised labeling in the United States includes a recommendation to limit single IV doses to no more than 16 mg, avoid use of <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> in patients with congenital long QT syndrome, and to use ECG monitoring in certain patients, including those with hypokalemia or hypomagnesemia, heart failure, and bradyarrhythmias, and in patients taking other medications that increase the risk of QTc prolongation  (<a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">table 4</a>).</p><p>Canadian guidelines that took effect in June 2014 place additional dosing restrictions on IV <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> to mitigate the risk of QT prolongation in older adults [<a href="#rid35">35</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients ≥75 years of age, the initial IV dose should not exceed 8 mg.</p><p class="bulletIndent1"><span class="glyph">●</span>For patients age &lt;75, the initial IV dose should not exceed 16 mg.</p><p class="bulletIndent1"><span class="glyph">●</span>Subsequent IV doses must not exceed 8 mg and may be given four and eight hours after the initial dose.</p><p class="bulletIndent1"><span class="glyph">●</span>All IV doses must be diluted in 50 to 100 mL of <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> or other compatible fluid.</p><p class="bulletIndent1"><span class="glyph">●</span>All IV doses must be infused over no less than 15 minutes.</p><p></p><p>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F020103s038%2C020605s022%2C020781s022lbl.pdf&amp;token=dXVV3%2FfVvvaaJ309XH0CIfyQuNPu%2BhXf8kB0Vavxt8VRJhVZnKs4sRW9Oi4uOPkgVksNgsn4uIQs2UlQmx4HbQImUNsKGgIDvmFX2YNUa5FfOx2CFj90px1g485CxhZ%2F&amp;TOPIC_ID=1151" target="_blank">FDA-approved label for oral ondansetron</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F020007s049lbl.pdf&amp;token=uM1mj%2Fqrwrsny2uf9iNAvH6nQ2O63uFuFcy2X3YdgipZ7WiwjM8vW3qtMR6jjEtKOhbXNF%2B%2FM%2BwftxrO8QpwlPTsGep2RzZKwRXmRTo2ybM%3D&amp;TOPIC_ID=1151" target="_blank">IV ondansetron</a> also recommend advising and monitoring patients for signs and symptoms of myocardial ischemia after oral administration of the drug, and during as well as after IV administration. Most of the cases have occurred immediately after IV administration; symptoms typically resolve with prompt treatment.</p><p class="headingAnchor" id="H6"><span class="h3">Palonosetron</span><span class="headingEndMark"> — </span>The second-generation agent <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> has a 30- to 100-fold higher affinity for the 5-HT3 receptor and a significantly longer half-life (40 hours) compared with first-generation 5-HT3 receptor antagonists. In contrast to first-generation 5-HT3 antagonists, QTc prolongation has not been described with palonosetron [<a href="#rid36">36,37</a>].</p><p>As a single agent, <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> is more effective than <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> or <a class="drug drug_general" data-topicid="8592" href="/z/d/drug information/8592.html" rel="external">dolasetron</a> at preventing emesis due to chemotherapy agents of varying emetogenicity [<a href="#rid38">38-40</a>]. This was illustrated by a multicenter trial in 592 patients, the majority of whom received <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a> and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> for breast cancer; a minority received cisplatin- and carboplatin-based chemotherapy regimens [<a href="#rid38">38</a>]. Subjects were randomly assigned to a single IV dose of palonosetron at one of two dose levels (0.25 or 0.75 mg IV) or dolasetron (100 mg). More patients treated with palonosetron (0.25 mg) had complete control of both acute (63 versus 53 percent) and delayed emesis (54 versus 39 percent) compared with dolasetron. The dose of 0.75 mg was not significantly superior compared with 0.25 mg. A similarly designed trial also demonstrated superiority for palonosetron compared with ondansetron [<a href="#rid39">39</a>].</p><p>When used in combination with glucocorticoids, <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> provides superior control of delayed emesis compared with first-generation 5-HT3 receptor antagonists combined with glucocorticoids [<a href="#rid41">41-43</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a phase III, double-blind, double-dummy trial, 1143 patients receiving highly emetogenic chemotherapy (<a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or an anthracycline/<a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> combination for breast cancer) were randomly assigned to <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> plus either <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> or <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">granisetron</a> on day 1 prior to chemotherapy; all patients received dexamethasone on days 2 and 3 [<a href="#rid41">41</a>]. During the acute phase, the rate of complete control of CINV was similar (75 versus 73 percent with palonosetron and granisetron, respectively), but during the delayed phase (24 to 120 hours), complete responses occurred in significantly more patients receiving palonosetron (57 versus 45 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second phase III trial in which 667 patients receiving cisplatin-based chemotherapy were randomly assigned to <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> (0.25 mg), palonosetron (0.75 mg), or <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> (32 mg) no significant differences in antiemetic control were noted between palonosetron and ondansetron [<a href="#rid42">42</a>]. Approximately two-thirds of patients received concomitant <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>. In this subset of patients, complete response rates were numerically higher in both palonosetron arms compared with ondansetron during the first 24 hours. During the delayed (24 to 120 hours) phase, complete response was significantly higher in the 0.25 mg palonosetron arm compared with the ondansetron arm (42 versus 29 percent, p = 0.021).</p><p></p><p>Two questions arising from the design of these studies are whether the efficacy differences noted would have persisted with protracted dosing (days 2 and 3) of the first-generation 5-HT3 receptor antagonists, which have a much shorter half-life than <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a>, or with the addition of an NK1R antagonist, which all evidence-based guidelines recommend in this setting. At least one phase III study has failed to demonstrate the superiority of palonosetron over <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">granisetron</a> in patients also receiving an NK1R antagonist for the primary endpoint of complete response for the 0 to 120 hour period following cisplatin-based chemotherapy; however, the palonosetron arm was superior for multiple secondary endpoints [<a href="#rid44">44</a>].</p><p>Updated antiemetic guidelines from the National Comprehensive Cancer Network (NCCN) recommend <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> as the preferred 5-HT3 antagonist for patients who receive moderately emetogenic chemotherapy [<a href="#rid8">8</a>].</p><p>By contrast, updated guidelines from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmascc.org%2Fresources%2Fmascc-guidelines%2F&amp;token=795%2BxPqISNblxEq%2B8WXBBjoU8Peh%2FAysEk%2FPCZ98NtpEW3K8qd7SLaghSimhgt0C&amp;TOPIC_ID=1151" target="_blank">Multinational Association of Supportive Care in Cancer (MASCC)/European Society for Medical Oncology (ESMO)</a> and the American Society of Clinical Oncology (ASCO) do not specify a preferred 5-HT3 antagonist for patients receiving moderately emetogenic chemotherapy [<a href="#rid5">5,7</a>].</p><p>A noninferiority trial documented similarity between the oral and IV formulations and validated the correct <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> dose (0.5 mg oral). The oral formulation of palonosetron, which was approved by the FDA in 2008, is not marketed in the United States but is available in a number of European countries.</p><p class="headingAnchor" id="H3623860416"><span class="h4">Dexamethasone duration in patients receiving moderately emetogenic chemotherapy</span><span class="headingEndMark"> — </span>A number of studies have addressed the issue of whether single day <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> is comparable in efficacy to multiple day dexamethasone when combined with <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> in patients receiving moderately emetogenic chemotherapy [<a href="#rid45">45</a>]. These have included both anthracycline and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (AC) and non-AC chemotherapy regimens. This question has been previously resolved for patients receiving AC, which is now considered highly emetogenic; in this situation, a single day 1 dose of dexamethasone in combination with a 5-HT3 receptor antagonist, an NK1 receptor antagonist, and <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> has been defined as the preferred regimen. (See <a class="local">'Anthracycline combined with cyclophosphamide'</a> above.)</p><p>With carboplatin-containing moderately emetogenic regimens, single day 1 <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> combined with a 5-HT3 receptor antagonist and an NK1 receptor antagonist is recommended. (See <a class="local">'Carboplatin-based regimens'</a> above.)</p><p>For non-AC, non-carboplatin moderately emetogenic chemotherapy regimens, support for a one-day <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> regimen when <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> is employed as the 5-HT3 receptor is provided by a randomized trial conducted in Japan [<a href="#rid46">46</a>]. Three hundred and five patients receiving a variety of moderately emetogenic regimens were randomized to receive palonosetron on day 1 combined with either dexamethasone on day 1 only versus dexamethasone administered on days 1 through 3. No patients received AC, and only 12 percent of patients received <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>. Antiemetic control was comparable between the two study arms.</p><p class="headingAnchor" id="H2079608387"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>5-HT3 receptor antagonists are generally safe, with a favorable side effect profile (predominantly low-grade headache, malaise, and constipation).</p><p>A few reports have appeared suggesting a potential link between 5-HT3 receptor antagonists and the serotonin syndrome [<a href="#rid47">47</a>], which is caused when serotonin accumulates to high levels in vivo. Symptoms include confusion, agitation, restlessness, muscle twitching or stiffness, fever, sweating, fluctuations in heart rate and blood pressure, as well as nausea and/or vomiting, loss of consciousness, and coma; the syndrome can be fatal if not treated. (See  <a class="medical medical_review" href="/z/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p>However, in nearly all cases, the use of concomitant medications with a 5-HT3 receptor antagonist has limited the ability to establish a definitive association. Nevertheless, caution is advised when using 5-HT3 receptor antagonists in combination with other drugs that affect serotonin levels  (<a class="graphic graphic_table graphicRef64604" href="/z/d/graphic/64604.html" rel="external">table 5</a>).</p><p class="headingAnchor" id="H7"><span class="h2">Neurokinin-1 receptor antagonists</span><span class="headingEndMark"> — </span>The introduction of the NK1R antagonists <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> and <a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">fosaprepitant</a> (a parenteral water-soluble prodrug of aprepitant that is effective as a one-day treatment (see <a class="local">'One- versus three-day administration'</a> below)) has significantly improved the ability to prevent both acute and delayed CINV in patients receiving highly emetic, IV-administered chemotherapy  (<a class="graphic graphic_table graphicRef58756" href="/z/d/graphic/58756.html" rel="external">table 1</a>). Randomized trials also support a role for NK1R antagonists with the moderately emetogenic agent <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> as well [<a href="#rid48">48-51</a>]. These studies demonstrated that the rate of complete response (no emesis, no rescue) increased by 10 to 15 percent with the addition of an NK1R antagonist to <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> and a 5-HT3 receptor antagonist compared with the combination of dexamethasone and a 5-HT3 receptor antagonist. On the other hand, the value of an NK1R antagonist is less certain for <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>; two large randomized trials have come to opposite conclusions [<a href="#rid52">52,53</a>].</p><p><a class="drug drug_general" data-topicid="103785" href="/z/d/drug information/103785.html" rel="external">Rolapitant</a> is a potent selective NK1R antagonist with a longer plasma half-life (approximately seven days) than <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a>. Netupitant plus <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> (NEPA) is a novel, oral fixed-dose combination containing 300 mg of netupitant (a highly selective NK1R antagonist) and 0.5 mg of the 5-HT3 receptor antagonist palonosetron. Casopitant is another NK1R antagonist that can be given as a single day 1 oral dose or in a mixed IV plus oral three-day schedule in conjunction with <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> and <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a>; commercial development of this agent is not being pursued.</p><p>Although few studies have directly compared these agents head to head, the available evidence suggests that they have similar efficacy for control of acute and delayed emesis, at least in the setting of highly emetogenic chemotherapy [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H238310204"><span class="h3">Aprepitant and fosaprepitant</span></p><p class="headingAnchor" id="H8"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>The benefit of combining an NK1R antagonist (<a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a>, <a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">fosaprepitant</a>, or casopitant) with an 5-HT3 receptor antagonist plus a glucocorticoid for the prevention of acute CINV was addressed in a meta-analysis of 17 trials, totaling 8740 patients who were receiving highly or moderately emetogenic chemotherapy [<a href="#rid55">55</a>]. The addition of an NK1R antagonist to standard antiemetic therapy significantly improved the rate of complete response (absence of emesis and no need for rescue antiemetics) in the overall (during the first 120 hours of chemotherapy, 72 versus 54 percent, odds ratio [OR] 0.51, 95% CI 0.46-0.57), acute (first 24 hours, OR 0.56, 95% CI 0.48-0.65), as well as delayed phase (OR 0.48, 95% CI 0.42-0.56). For other secondary outcomes (rate of emesis, absence of nausea), the addition of an NK1R antagonist was also superior to the control arm.</p><p>In subgroup analyses, benefit was seen for both highly emetogenic (complete response 73 versus 54 percent, OR 0.46, 95% CI 0.40-0.53) and moderately emetogenic chemotherapy (complete response 71 versus 54 percent, OR 0.59, 95% CI 0.61-0.67). There appeared to be no differences in treatment efficacy for <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a>/<a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">fosaprepitant</a> and casopitant. The use of an NK1R antagonist did not increase the risk of diarrhea, although the rates of hiccups and fatigue/asthenia were significantly higher. There was a suggestion that use of an NK1R antagonist increased the risk of a severe infection (6 versus 2 percent in a pooled analysis of three trials); however, this was not associated with an increased rate of neutropenia or febrile neutropenia.</p><p class="headingAnchor" id="H3798759"><span class="h5">Need for a 5-HT3 agent</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">Aprepitant</a> and <a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">fosaprepitant</a> improve control of CINV when combined with a type three 5-hydroxytryptamine (5-HT3) receptor antagonist and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>. Aprepitant plus dexamethasone alone is not as effective as the three-drug combination regimen. A 5-HT3 receptor antagonist remains necessary, at least in patients receiving cisplatin-based chemotherapy.</p><p>This was illustrated by a randomized trial in which patients receiving <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> chemotherapy were randomly assigned to the combination of <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> plus <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">granisetron</a>, granisetron, or aprepitant (on one of two schedules) [<a href="#rid56">56</a>]. All patients also received <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (20 mg orally) before cisplatin. While the three-drug combination blocked emesis in 80 percent of patients, dexamethasone plus either granisetron or aprepitant was effective in only 57 and 43 to 46 percent of cases, respectively.</p><p class="headingAnchor" id="H428644927"><span class="h4">One- versus three-day administration</span><span class="headingEndMark"> — </span>In the United States, both <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> and <a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">fosaprepitant</a> are approved for use in three-day schedules. However, a single-day dosing schedule for fosaprepitant was approved by the FDA based upon the results of a phase III trial involving 2247 patients receiving single-day <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (&gt;70 mg/m<sup>2</sup>)-based chemotherapy [<a href="#rid57">57</a>]. The control group received aprepitant administered in the standard three-day schedule along with <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>; this was compared with a single 150 mg dose of fosaprepitant combined with ondansetron on day 1 plus dexamethasone on days 2, 3, and 4. Complete antiemetic response rates were nearly identical between the aprepitant and fosaprepitant arms (72.3 versus 71.9 percent).</p><p>IV <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> has been FDA approved based solely on bioequivalence studies in human volunteers. There are different recommendations for dosing in patients receiving highly emetogenic chemotherapy (130 mg IV on day 1 only) and carboplatin-containing moderately emetogenic chemotherapy (100 mg IV on day 1 followed by 80 mg of oral aprepitant on days 2 and 3, or 130 mg IV on day 1 only) in conjunction with other agents. The data to support these different recommendations are not evident, as only bioequivalence studies are available and studies in actual patients receiving chemotherapy have not been conducted.</p><p class="headingAnchor" id="H1717074192"><span class="h3">Netupitant plus palonosetron and fosnetupitant</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral NEPA</strong> – Oral NEPA is a novel, oral fixed-dose combination containing 300 mg of netupitant (a highly selective NK1R antagonist) and 0.5 mg of <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a>, a pharmacologically and clinically distinct 5-HT3 receptor antagonist. (See <a class="local">'Palonosetron'</a> above.)</p><p></p><p class="bulletIndent1">Single-dose oral NEPA in conjunction with <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> for control of both acute and delayed nausea and emesis has been compared with <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> plus a 5-HT3 receptor antagonist and dexamethasone [<a href="#rid58">58-61</a>] in several randomized phase II and III trials conducted in populations receiving either moderately or highly emetogenic chemotherapy, all of which showed superiority or at least noninferiority for oral NEPA over the control arm. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Efficacy of oral NEPA over multiple cycles of chemotherapy was evaluated in a phase III randomized trial in which 413 patients receiving a variety of moderately (<a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>, <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>, <a class="drug drug_general" data-topicid="8663" href="/z/d/drug information/8663.html" rel="external">epirubicin</a>, <a class="drug drug_general" data-topicid="9326" href="/z/d/drug information/9326.html" rel="external">daunorubicin</a>) or highly emetogenic (<a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9316" href="/z/d/drug information/9316.html" rel="external">dacarbazine</a>, <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">carmustine</a>) chemotherapy were randomly assigned to oral NEPA given on day 1 with oral <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> versus a three-day regimen of <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> plus <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> and dexamethasone [<a href="#rid59">59</a>]. In both groups, dexamethasone was administered on days 1 through 4 for highly emetogenic chemotherapy and on day 1 only for moderately emetogenic chemotherapy. During cycle 1, complete response rates (no emesis and no need for rescue medication through hour 120) were 81 and 76 percent for oral NEPA and aprepitant/palonosetron, respectively, and antiemetic efficacy was maintained over multiple cycles.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Another trial compared oral NEPA with <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> in 1455 patients receiving <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> plus an anthracycline (either <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a> or <a class="drug drug_general" data-topicid="8663" href="/z/d/drug information/8663.html" rel="external">epirubicin</a>); all patients also received <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> on day 1 only [<a href="#rid61">61</a>]. The percentage of patients with a complete response (through hour 120) was significantly higher with oral NEPA (74 versus 67 percent, p = 0.001). Oral NEPA was well tolerated and had a similar safety profile to palonosetron.</p><p></p><p class="bulletIndent1">Based on several of these trials, oral NEPA was approved in the United States for prevention of chemotherapy-related nausea and vomiting in October 2014. An important point is that, if oral NEPA is used in the setting of anthracycline plus <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> chemotherapy and non-highly emetogenic regimens, routine maintenance antiemetic therapy is not recommended after day 1. If used with a cisplatin-containing regimen, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> is recommended on days 1 through 4.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fosnetupitant and</strong> <strong>IV NEPA</strong> – Fosnetupitant is an injectable phosphorylated prodrug of netupitant that appears similarly efficacious as <a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">fosaprepitant</a> when combined with <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> for prevention of CINV with cisplatin-based chemotherapy, but with a lower frequency of injection site reactions [<a href="#rid62">62,63</a>]. It is available primarily in Japan.</p><p></p><p class="bulletIndent1">However, an IV equivalent to oral NEPA (IV NEPA) that consists of 235 mg of fosnetupitant plus 0.25 mg of <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> is approved in the United States and European Union for prevention of CINV in patients receiving highly emetogenic chemotherapy, largely based upon a phase III safety study comparing oral versus IV NEPA [<a href="#rid64">64</a>]. IV NEPA has been studied for prevention of nausea and vomiting associated with a cisplatin-containing regimen [<a href="#rid65">65</a>] but not anthracycline plus <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> regimens.</p><p></p><p class="bulletIndent1">If IV NEPA is used, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2F210493s000lbl.pdf&amp;token=3f02d7lbs9y9umMzzLeT%2BrihkdJcur6jTx0OYwa2vDCuCaHt%2FDiAW9IPfytFFdp2kYKXa9IEV7%2BNWhNdE4lJ5H69pD%2BfKcz%2B6kM85UPWMwY%3D&amp;TOPIC_ID=1151" target="_blank">United States Prescribing Information</a> recommends that all patients receive <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> 8 mg once daily on days 1 through 4. Similar to <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> and <a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">fosaprepitant</a>, netupitant is also an inhibitor of CYP3A4, and a reduced dose of concurrently administered glucocorticoids is needed. (See <a class="local">'Inhibition of CYP3A4 and implications for concurrently used drugs'</a> below.)</p><p></p><p class="headingAnchor" id="H238310401"><span class="h3">Rolapitant</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="103785" href="/z/d/drug information/103785.html" rel="external">Rolapitant</a> is a potent selective NK1R antagonist with a longer plasma half-life (approximately seven days) than either <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> or <a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">fosaprepitant</a>. Safety and efficacy were established in three randomized, double-blind trials in which rolapitant (180 mg orally, one to two hours before chemotherapy administration) in combination with IV <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">granisetron</a> on day 1 and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (20 mg on day 1 followed by 8 mg twice daily on days 2 to 4 of cycle 1) was compared with a control therapy (placebo with the same dose and schedule of granisetron and dexamethasone) in patients receiving highly emetogenic (eg, <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or anthracycline plus <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>) or moderately emetogenic chemotherapy agents [<a href="#rid66">66,67</a>]. Patients treated with rolapitant had a significantly greater protection from delayed emesis, but there was less consistency in the acute phase of CINV, with the moderately emetogenic trial and one of the highly emetogenic studies failing to show a significant improvement in emesis control within 24 hours of chemotherapy.</p><p>Unlike <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> and <a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">fosaprepitant</a>, which are moderate inhibitors of CYP3A4, <a class="drug drug_general" data-topicid="103785" href="/z/d/drug information/103785.html" rel="external">rolapitant</a> does not inhibit this metabolic pathway, and therefore, no adjustment of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> dose is required. Rolapitant does inhibit the cytochrome P450 2D6 (CYP2D6) enzyme, which is responsible for metabolizing certain drugs, such as <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">thioridazine</a>; the use of both drugs together is not recommended.</p><p><a class="drug drug_general" data-topicid="103785" href="/z/d/drug information/103785.html" rel="external">Rolapitant</a> is approved in adults, in combination with other antiemetic agents, to prevent delayed nausea and vomiting associated with the initial and repeat courses of emetogenic cancer chemotherapy. No clinical trials have yet reported a definitive direct comparison of any of the available NK1R antagonists.</p><p><a class="drug drug_general" data-topicid="103785" href="/z/d/drug information/103785.html" rel="external">Rolapitant</a> was originally available for use orally or through IV. Postmarketing reports surfaced about anaphylaxis, anaphylactic shock, and other serious hypersensitivity reactions in patients receiving IV rolapitant emulsion, some requiring hospitalization [<a href="#rid68">68</a>]. The intravenous preparation was subsequently removed from the market in August 2020. (See  <a class="medical medical_review" href="/z/d/html/2413.html" rel="external">"Food allergens: Clinical aspects of cross-reactivity", section on 'Legumes: Peanut, soy, and others'</a>.)</p><p class="headingAnchor" id="H1067842309"><span class="h3">Inhibition of CYP3A4 and implications for concurrently used drugs</span><span class="headingEndMark"> — </span>NK1R antagonists such as <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a>, <a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">fosaprepitant</a>, and netupitant (but not <a class="drug drug_general" data-topicid="103785" href="/z/d/drug information/103785.html" rel="external">rolapitant</a>) are moderate inhibitors of the cytochrome P450 3A4 enzyme (CYP3A4), which is particularly important in drug metabolism [<a href="#rid69">69</a>]. CYP3A4 is responsible for the metabolism of glucocorticoids, and these agents result in higher exposure for any given dose of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>. Thus, for patients treated with aprepitant, the dose of dexamethasone was reduced in clinical trials from 20 to 12 mg on day 1, and from 8 mg twice daily to 8 mg daily on days 2 through 4 [<a href="#rid70">70-72</a>]. With a single dose of fosaprepitant on day 1, the impaired metabolism of dexamethasone is on days 1 and 2 only, and the dexamethasone dose on days 1 and 2 must be reduced. On days 3 and 4, the dexamethasone dose is 8 mg twice daily [<a href="#rid57">57</a>].</p><p>Importantly, this dose reduction applies only when glucocorticoids are used as antiemetics in conjunction with NK1R antagonists, <strong>not</strong> when given as an antitumor component of a chemotherapy regimen.</p><p>Theoretically, <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a>, <a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">fosaprepitant</a> and netupitant could decrease the clearance of drugs metabolized by CYP3A4 (<a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a>, vinca alkaloids), resulting in prolonged exposure and increased toxicity. However, there is no clinical evidence that this actually occurs [<a href="#rid72">72,73</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Glucocorticoids</span><span class="headingEndMark"> — </span>Short courses of glucocorticoids are widely used both as single agents for regimens with low risk of causing CINV and in combination with 5-HT3 receptor inhibitors and/or NK1R antagonists for more emetic chemotherapy regimens. When used in this fashion, glucocorticoids have a high therapeutic index. Although the various glucocorticoids are probably equally effective when used at an appropriate dose, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> has been the most extensively evaluated and is the most widely used.</p><p class="headingAnchor" id="H14"><span class="h3">Single agent</span><span class="headingEndMark"> — </span>Single-agent <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> has been compared with either placebo or no treatment in a number of randomized trials. A meta-analysis of 32 randomized trials evaluated 5613 patients who received moderately or highly emetogenic chemotherapy [<a href="#rid74">74</a>]. Dexamethasone was superior to placebo or no treatment for complete protection from both acute emesis (risk ratio [RR] 1.30) and delayed emesis (RR 1.30). However, dexamethasone as a single agent is insufficient to control CINV in most of these patients [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H15"><span class="h3">Combination with a 5-HT3 antagonist</span><span class="headingEndMark"> — </span>Glucocorticoids alone represent insufficient first-line therapy for patients receiving either moderate or highly emetic chemotherapy agents. However, the antiemetic efficacy of the type three 5-hydroxytryptamine (5-HT3) receptor antagonists is significantly enhanced by the addition of a glucocorticoid [<a href="#rid11">11,75-79</a>].</p><p>Benefit for combined therapy was shown in a meta-analysis of 3791 patients enrolled in 22 randomized trials, in which a 5-HT3 receptor antagonist plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> was compared with a 5-HT3 antagonist plus placebo or no treatment in patients receiving moderate or highly emetic chemotherapy [<a href="#rid74">74</a>]. The pooled RR for emesis protection was 1.25, indicating that the addition of dexamethasone increased the chance of no acute vomiting by 25 percent.</p><p class="headingAnchor" id="H2966687393"><span class="h3">Patients receiving immune checkpoint inhibitors</span><span class="headingEndMark"> — </span>Systemic glucocorticoids may be avoided in patients receiving immune checkpoint inhibitors (ICIs) due to concerns that they might attenuate the benefit of ICI immunotherapy, but clinical practice is variable and clinical trials have variably allowed versus disallowed the use of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> as an antiemetic. The available data from randomized trials do not support inferior outcomes in patients who receive dexamethasone as a component of the antiemetic regimen in patients receiving combination therapy with cytotoxic chemotherapy plus an ICI [<a href="#rid80">80-82</a>]. Given these findings, updated 2020 antiemetic guidelines from ASCO specifically state that the addition of an ICI to chemotherapy does not change the guideline recommendation for an antiemetic regimen that is based on the emetogenicity of the agents administered [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H16"><span class="h3">Dose</span><span class="headingEndMark"> — </span>The impact of glucocorticoid dose was explored in a double-blind trial that randomly assigned 531 patients receiving <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> ≥50 mg/m<sup>2</sup> to one of four IV doses of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> administered by a 15-minute infusion prior to cisplatin administration [<a href="#rid83">83</a>]. All patients received 8 mg of <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> as well. At doses of 20, 12, 8, and 4 mg, complete protection from vomiting was achieved in 83, 79, 69, and 69 percent of patients, respectively, and nausea was prevented in 71, 67, 61, and 61 percent.</p><p>The optimal dose of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> for highly to moderately emetic chemotherapy not containing <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> was evaluated by the Italian Group for Antiemetic Research [<a href="#rid84">84</a>]. In this trial, all patients received IV <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> and were randomized to one of three schedules of dexamethasone (either 8 or 24 mg IV prior to chemotherapy, or 8 mg IV before treatment followed by 4 mg every six hours). Rates of complete protection from acute or delayed emesis were similar among the groups, and the authors concluded that a single 8 mg IV dose prior to chemotherapy represented the appropriate dexamethasone regimen.</p><p>As noted above, the dose of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> is reduced when it is in combination with specific NK1R antagonists (<a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a>, <a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">fosaprepitant</a>, netupitant). (See <a class="local">'Inhibition of CYP3A4 and implications for concurrently used drugs'</a> above.)</p><p class="headingAnchor" id="H2991588035"><span class="h2">Olanzapine</span><span class="headingEndMark"> — </span>Conventional antiemetics are more successful at preventing emesis than at preventing nausea, particularly delayed nausea. <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">Olanzapine</a>, a second-generation antipsychotic that blocks serotonin 5-hydroxytryptamine (5-HT2) receptors and dopamine D2 receptors, may be a particularly useful agent for the prevention of both acute and delayed nausea and vomiting.</p><p>The superiority of a prophylactic regimen including <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> over other antiemetic regimens not including olanzapine was addressed in a meta-analysis of 14 randomized trials in patients receiving highly or moderately emetogenic chemotherapy [<a href="#rid85">85</a>]. Compared with placebo, the addition of olanzapine to standard antiemetic therapy doubled the likelihood of no nausea or vomiting during chemotherapy from 25 to 50 percent (RR 1.98, 95% CI 1.59-2.47). Olanzapine also reduced delayed nausea (RR for being free of delayed nausea 1.71, 95% CI 1.40-2.09) and vomiting (RR 1.28, 95% CI 1.14-1.42), but the impact on acute nausea and vomiting was uncertain. Olanzapine also may increase adverse effects and probably increases somnolence and fatigue during treatment compared with no treatment or placebo. A subsequent network meta-analysis of antiemetic regimens for highly emetogenic chemotherapy also concluded that olanzapine-containing regimens were the most efficacious for preventing CINV in this setting [<a href="#rid86">86</a>].</p><p>In the most influential trial, 380 patients receiving highly emetogenic chemotherapy (<a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> ≥70 mg/m<sup>2</sup> or <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>/<a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>) were randomly assigned to <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> or <a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">fosaprepitant</a>, and a 5-HT3 receptor antagonist with either <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> (10 mg daily, orally, on days 1 through 4) or placebo [<a href="#rid87">87</a>]. The proportion of no patients with chemotherapy-induced nausea (the primary endpoint) was significantly higher with olanzapine, both in the first 24 hours after chemotherapy (74 versus 45 percent) and in the delayed period (42 versus 25 percent, p = 0.002). Rates of complete response (no emesis and no use of rescue medication) were also higher with olanzapine in the acute phase (86 versus 65 percent), delayed phase (67 versus 52 percent), and over the 120-hour period (64 versus 41 percent). The 41 percent complete response rate over the entire 120-hour period for the placebo group is very low by modern standards. Although not reported in the full manuscript, superiority for the olanzapine-containing arm was demonstrated in a subset analysis of both the cisplatin- and anthracycline/cyclophosphamide-treated patients [<a href="#rid88">88</a>]. The addition of olanzapine resulted in more sedation on day 2 (severe in 5 percent), which resolved thereafter, despite the continued use of olanzapine.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – The optimal dose of prophylactic <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> is not yet established. Although the phase III study described above used 10 mg daily, 5 mg, rather than 10 mg, may be a more appropriate dose for most patients, given the potential for excess sedation with the 10 mg dose. The following data inform this debate:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A relatively small randomized phase II trial in 153 patients receiving cisplatin-based chemotherapy showed similar activity for the 5 mg as compared with the 10 mg dose of <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>, with a more favorable somnolence profile [<a href="#rid89">89</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The two doses were directly compared in a trial conducted in a broader population of patients receiving highly emetogenic chemotherapy (37 cisplatin-based and 104 <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a> plus <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>); patients were randomized to oral <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> (daily on days 1 through 3) or 10 mg or 5 mg of <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> (both administered daily on days 1 through 4); all received <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> [<a href="#rid90">90</a>]. The primary endpoint was a no nausea rate through the entire five-day assessment period. A nonsignificantly higher proportion of patients given olanzapine 10 mg (43 percent) or 5 mg (37 percent) experienced no nausea compared with aprepitant (33 percent) during the 5-day period, but a significantly lower proportion of those receiving 10 mg olanzapine had moderate to severe delayed nausea compared with aprepitant (9 versus 28 percent); the difference with olanzapine 5 mg (19 percent) was not significant. Other efficacy measures (including complete control of CINV and the need for rescue antiemetics) were similar among the three groups. Lower-dose olanzapine was not associated with a lesser proportion of patients who reported sleepiness (42 versus 41 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Additional information is available from a placebo-controlled phase III trial of lower dose <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> (5 mg daily on days 1 through 4) versus placebo, both in conjunction with standard antiemetic therapy in 710 patients receiving cisplatin-based chemotherapy [<a href="#rid91">91</a>]. There was a statistically and clinically significant improvement in complete control of nausea and vomiting in both the acute and delayed phases with olanzapine, and a minimal impact on daytime sleepiness compared with standard antiemetics without olanzapine.</p><p></p><p class="bulletIndent1">Two separate meta-analyses of these and other trials have concluded that prophylactic regimens utilizing 5 mg <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> may be as efficacious as 10 mg regimens [<a href="#rid92">92,93</a>]. However, in our view, these data support the use of the 5 mg olanzapine dose over the 10 mg dose in the setting of cisplatin-based highly emetogenic chemotherapy. For patients receiving an anthracycline plus <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, there are insufficient data to exclude the possibility that a lower olanzapine dose may not be as effective as the higher 10 mg dose for prevention of CINV.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of delayed emesis</strong> – A separate issue is whether <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> can replace an NK1R antagonist for prevention of delayed emesis in patients receiving highly emetogenic chemotherapy. This issue was addressed in the following trials:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one phase III trial 247 patients receiving <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a> plus <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> were randomly assigned to <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> (10 mg orally on the day of chemotherapy, and then 10 mg once daily on days 2 through 4) or <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> (125 mg orally prior to chemotherapy, followed by 80 mg orally on days 2 and 3), both in combination with <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> (0.25 IV on the day of chemotherapy) plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> [<a href="#rid94">94</a>]. Dexamethasone (20 mg) was only given on the day of chemotherapy, while the aprepitant group received dexamethasone 12 mg on the day of chemotherapy followed by dexamethasone 4 mg twice daily on days 2 and 3. Following cycle 1, rates of prevention of acute nausea (87 percent in both the olanzapine and aprepitant groups) and of complete control of acute (97 versus 87 percent) and delayed vomiting (77 versus 73 percent) were similar. However, patients treated with olanzapine had a significantly higher rate of nausea control in the delayed period (69 versus 38 percent). The results were maintained during cycles 2 to 4. This trial was not included in the Cochrane review of olanzapine cited above [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Similar results were noted in the small randomized Thai trial described above, in which patients receiving highly emetogenic chemotherapy were randomized to oral <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> (daily on days 1 through 3) or 10 mg or 5 mg of <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> (both administered daily on days 1 through 4); all received <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> [<a href="#rid90">90</a>]. A significantly higher proportion of patients given olanzapine 10 mg (43 percent) or 5 mg (37 percent) experienced no nausea compared with aprepitant (33 percent) during the five-day period, and a significantly lower proportion of those receiving 10 mg olanzapine had moderate to severe delayed nausea compared with aprepitant (9 versus 28 percent). Other efficacy measures (including complete control of CINV and the need for rescue antiemetics) were similar between olanzapine and aprepitant.</p><p></p><p>The benefit of <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> for management of breakthrough emesis is addressed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/134925.html" rel="external">"Management of poorly controlled or breakthrough chemotherapy-induced nausea and vomiting in adults"</a>.)</p><p class="headingAnchor" id="H502786618"><span class="h2">Thalidomide</span><span class="headingEndMark"> — </span>NK1R antagonists effectively prevent delayed emesis from highly emetogenic chemotherapy, but they are not available worldwide, including in China.</p><p>The benefit of <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> in this setting was addressed in a trial in which 656 patients scheduled to receive highly emetogenic chemotherapy that included <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or a <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>/anthracycline combination were randomly assigned to thalidomide 100 mg twice daily on days 1 to 5 versus placebo; all patients received <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> on day 1 and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> on days 2 through 4 [<a href="#rid95">95</a>]. The primary endpoint was no emesis or use of rescue medication in the delayed phase (25 to 120 hours) or overall (0 to 120 hours) after a single treatment cycle. Compared with placebo, delayed and overall complete response rates with thalidomide were significantly higher (77 versus 62 and 66 versus 53 percent, respectively). Rates of no nausea were also higher with thalidomide. The thalidomide group had higher rates of sedation, dizziness, constipation, and dry mouth. Given these toxicities, the association of neuropathy and thromboembolism with this agent (which is not well assessed in a trial only evaluating a single treatment cycle), its expense, and restricted access because of a history of causing fetal anomalies, thalidomide is not preferred over an NK1R antagonist for prevention of delayed emesis. However, the combination of thalidomide plus palonosetron and dexamethasone is an option for prevention of delayed emesis in patients who lack access to NK1R antagonists.</p><p class="headingAnchor" id="H17"><span class="h2">Other agents</span><span class="headingEndMark"> — </span>Other agents that have been used in the treatment or prevention of CINV include dopaminergic antagonists such as phenothiazines (eg, <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">prochlorperazine</a>, <a class="drug drug_general" data-topicid="10147" href="/z/d/drug information/10147.html" rel="external">levomepromazine</a> outside of the United States), <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a>, and butyrophenones, as well as cannabinoids such as <a class="drug drug_general" data-topicid="9394" href="/z/d/drug information/9394.html" rel="external">dronabinol</a>. These agents have a lower therapeutic index than the 5-HT3 receptor antagonists, NK1R antagonists, and glucocorticoids for highly or moderately emetogenic chemotherapy regimens. Their use should be restricted to patients who are intolerant of or refractory to these first-line agents. The benefits of synthetic oral cannabinoids in this setting remain controversial given the lack of evidence on their safety and efficacy [<a href="#rid96">96-100</a>]. Phenothiazines could be used as an alternative to single-agent <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> for those receiving chemotherapy with a low risk of emesis, if a glucocorticoid is contraindicated [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/2538.html" rel="external">"Characteristics of antiemetic drugs"</a>.)</p><p>Another drug that may be useful as an adjunct to conventional antiemetic agents is <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a>, but it is not recommended as a single-agent antiemetic [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H18"><span class="h1">PREVENTION OF DELAYED EMESIS</span><span class="headingEndMark"> — </span>Delayed emesis is defined by its occurrence more than 24 hours after chemotherapy. Although it is most common following high-dose <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid101">101-103</a>], delayed emesis may occur with other agents as well [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H127218108"><span class="h2">Regimens with a high risk of delayed emesis</span><span class="headingEndMark"> — </span>The risk of delayed emesis after <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (doses &gt;70 mg/m<sup>2</sup>) ranges between 60 and 90 percent in the absence of effective prophylaxis. The risk of delayed emesis without any prophylaxis is estimated to be between 20 and 30 percent in patients receiving chemotherapy with an anthracycline plus <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (AC) [<a href="#rid104">104</a>].</p><p>Although the risk of delayed emesis has been best studied with high-dose <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and the combination of <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a> plus <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (in patients treated for breast cancer), several moderately emetogenic agents are also associated with delayed emesis. These include doxorubicin ≥40 mg/m<sup>2</sup> as a single agent or ≥25 mg/m<sup>2</sup> in combination with other chemotherapeutic agents (especially cyclophosphamide), <a class="drug drug_general" data-topicid="8663" href="/z/d/drug information/8663.html" rel="external">epirubicin</a> ≥75 mg/m<sup>2</sup> as a single agent or ≥50 mg/m<sup>2</sup> when given in combination with other agents, combinations of cyclophosphamide ≥600 mg/m<sup>2</sup> with other drugs, <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> ≥300 mg/m<sup>2</sup>, and <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> (as used in the FOLFOX [oxaliplatin plus short-term infusional <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> and <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a>] regimen for advanced colorectal cancer) [<a href="#rid23">23,105-108</a>]. One study found that, among 68 patients treated with one of these regimens who had no postchemotherapy vomiting in the 24 hours after administration of prechemotherapy <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, 28 (41 percent) vomited in the next four days when no further antiemetics were given [<a href="#rid23">23</a>]. This frequency was reduced to 15 of 75 (20 percent) when ondansetron was continued.</p><p class="headingAnchor" id="H127217965"><span class="h3">Management</span><span class="headingEndMark"> — </span>A variety of antiemetic agents have demonstrated value in the prevention of delayed emesis. The most important classes of agents have been the neurokinin-1 receptor (NK1R) antagonists [<a href="#rid55">55</a>], corticosteroids [<a href="#rid101">101,103</a>], and more recently, <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> [<a href="#rid87">87</a>]. The data supporting the latter agents in delayed emesis are reviewed in the sections above. Additional agents that may have some value in some delayed emesis settings include <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> and the type three 5-hydroxytryptamine (5-HT3) receptor antagonists.</p><p class="headingAnchor" id="H1690019631"><span class="h4">NK1R antagonist plus dexamethasone and 5-HT3 antagonist</span><span class="headingEndMark"> — </span>For most patients undergoing treatment with <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or other (non-AC) highly emetogenic chemotherapy agents the recommended regimen to prevent delayed emesis is an NK1R antagonist combined with <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, a type three 5-hydroxytryptamine (5-HT3) antagonist, and <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> on day 1, followed by a combination of dexamethasone on days 2 to 4 and olanzapine on days 2 to 4. (See <a class="local">'Cisplatin and other highly emetogenic single agents'</a> above.)</p><p>The optimal way to prevent delayed emesis in patients receiving AC for breast cancer is controversial. Data supporting <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> beyond day 1 when an NK1R antagonist is used are very limited:</p><p class="bulletIndent1"><span class="glyph">●</span>Phase III trials using the new NK1R antagonists netupitant and <a class="drug drug_general" data-topicid="103785" href="/z/d/drug information/103785.html" rel="external">rolapitant</a> used <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> on day 1 only and achieved high rates of total control of CINV [<a href="#rid66">66,109</a>]. (See <a class="local">'Netupitant plus palonosetron and fosnetupitant'</a> above and <a class="local">'Rolapitant'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another randomized trial conducted exclusively in this population that used <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> or <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> on days 2 and 3, and gave <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> on day 1 only also reported high rates of total control of CINV [<a href="#rid72">72</a>]. (See <a class="local">'Efficacy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another trial comparing <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> versus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> on days 2 and 3 for preventing delayed emesis after AC, with all patients receiving aprepitant, <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a>, and dexamethasone on day 1, showed no significant difference in outcomes [<a href="#rid110">110</a>].</p><p></p><p>Whether there is benefit for continuing <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> on days 2 and 3 after a long-acting NK1R antagonist on day 1 (eg, <a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">fosaprepitant</a>, <a class="drug drug_general" data-topicid="103785" href="/z/d/drug information/103785.html" rel="external">rolapitant</a>) or days 1 to 3 (<a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a>) plus a 5-HT3 antagonist on day 1 is better than just the long-acting NK1R antagonist plus a 5-HT3 antagonist with dexamethasone on day 1 was directly addressed in a placebo-controlled double-blind phase III trial conducted in 396 patients receiving highly emetogenic regimens (<a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> ≥50 mg/m<sup>2</sup> or AC) [<a href="#rid111">111</a>]. All patients received <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> on day 1, and approximately 80 percent received a three-day aprepitant-containing regimen; the remainder had fosaprepitant on day 1. Complete response rates, defined as no emesis and no rescue medications during the overall acute and delayed phase (to 120 hours), were similar in both the three-day and one-day dexamethasone groups (46.9 versus 44 percent). The authors concluded that dexamethasone administration on days 2 and 3 can be spared when combined with an NK1R antagonist plus palonosetron. This conclusion appears most valid for patients receiving AC, as these patients comprised the majority (77 percent) of study participants. For the 23 percent of patients receiving cisplatin, a clear trend favoring the three-day dexamethasone arm was noted.</p><p>What has not been studied is if <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> used on day 1 followed by <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> and aprepitant on days 2 to 3 is better than aprepitant alone continued on days 2 and 3, and whether day 2 and 3 dexamethasone is needed in patients receiving other 5-HT3 antagonists on day 1 plus an NK1R antagonist. Until these studies are done, it is difficult to conclude that there is benefit for adding dexamethasone on days 2 and 3 in patients receiving AC who have received a long-acting NK1R antagonist on day 1.</p><p class="headingAnchor" id="H1486474254"><span class="h4">Metoclopramide in patients receiving cisplatin</span><span class="headingEndMark"> — </span>All of the trials examining the benefit of <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> to prevent delayed CINV used a three-day schedule of administration in conjunction with oral glucocorticoids. Single-day administration is approved for <a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">fosaprepitant</a> but not aprepitant. (See <a class="local">'Efficacy'</a> above.)</p><p>The use of <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> as a substitute for <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> on days 2 and 3 was addressed in a randomized trial in which 303 previously untreated patients received a cisplatin-based chemotherapy regimen [<a href="#rid112">112</a>]. All patients received the same regimen to prevent acute emesis on day 1 (aprepitant 125 mg, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> 8 mg, and <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> 0.25 mg) and were randomly assigned to dexamethasone 8 mg daily on days 2 to 4 plus aprepitant 80 mg daily on days 2 and 3 <strong>or</strong> to dexamethasone 8 mg twice daily plus metoclopramide 20 mg four times a day on days 2 to 4. The primary endpoint was complete response (no vomiting or rescue medication on days 2 through 5 after chemotherapy). The complete response rate was not significantly different (80.3 versus 82.5 for aprepitant and metoclopramide, respectively), as were all secondary endpoints, including no nausea, and adverse events were not significantly different. The authors concluded that aprepitant was not superior to metoclopramide for control of delayed emesis after <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> when used in conjunction with dexamethasone after day 1 of chemotherapy.</p><p>Given that many institutions have switched over to day 1 single-dose <a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">fosaprepitant</a> followed by <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> alone on days 2 to 3, rather than three-day <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> plus dexamethasone, to prevent delayed emesis, the relevance of these results to current clinical practice is unclear.</p><p class="headingAnchor" id="H2927140587"><span class="h4">5-HT3 antagonists alone</span><span class="headingEndMark"> — </span>Conflicting results have been described with the use of first-generation type three 5-hydroxytryptamine (5-HT3) receptor antagonists as single agents for protection against delayed emesis [<a href="#rid101">101,113-117</a>]. Although some benefit has been seen when these agents are used as monotherapy, the benefit has not been as great as that seen with glucocorticoids. Furthermore, continuing a 5-HT3 receptor antagonist beyond 24 hours along with glucocorticoids did not confer additional benefit compared with corticosteroids alone. Thus, the use of 5-HT3 receptor antagonists as a sole maneuver to prevent delayed emesis in patients receiving <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> is <strong>not</strong> recommended.</p><p>The second-generation 5-HT3 receptor antagonist <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> seems to be superior to other 5-HT3 receptor antagonists for the treatment of delayed emesis due to cisplatin-based chemotherapy:</p><p class="bulletIndent1"><span class="glyph">●</span>In a phase III trial of patients receiving cisplatin-based chemotherapy, <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> (at one of two doses, either 0.25 mg or 0.75 mg) yielded higher rates of emetic control compared with <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> in preventing delayed emesis (complete response rates of 45 and 48 versus 39 percent, respectively), although the results were not statistically significant [<a href="#rid42">42</a>]. However, in a subset analysis, palonosetron 0.25 mg was superior to ondansetron for control of delayed and overall emesis in patients receiving concomitant <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The superiority of <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> for prevention of delayed emesis was also shown in another phase III trial in which 1114 patients receiving <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or an AC combination were randomly assigned to a single dose of palonosetron or <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">granisetron</a> 30 minutes prior to chemotherapy, with all patients receiving <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> for three days [<a href="#rid41">41</a>]. Significantly better control of delayed emesis was achieved in both the cisplatin and AC subgroups on the palonosetron arm (complete response 57 versus 45 percent with granisetron).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A third phase III trial also supports superiority of <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> over <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">granisetron</a> in patients also receiving an NK1R antagonist for prevention of delayed emesis [<a href="#rid44">44</a>].</p><p></p><p class="headingAnchor" id="H3254447597"><span class="h4">Thalidomide</span><span class="headingEndMark"> — </span>Another option for prevention of delayed emesis with highly emetogenic chemotherapy, particularly in countries where NK1R antagonists are not available, is <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> in combination with <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>. (See <a class="local">'Thalidomide'</a> above.)</p><p class="headingAnchor" id="H22"><span class="h2">Moderate-risk regimens</span><span class="headingEndMark"> — </span>The incidence of delayed emesis following treatment with moderate-risk regimens is not well characterized. Cyclophosphamide- or doxorubicin-based regimens used for diseases other than breast cancer, as well as carboplatin- and oxaliplatin-containing regimens, can cause delayed emesis. (See  <a class="medical medical_review" href="/z/d/html/1150.html" rel="external">"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting", section on 'Delayed emesis'</a>.)</p><p class="headingAnchor" id="H2810429526"><span class="h3">Carboplatin-containing regimens</span><span class="headingEndMark"> — </span>There are clear supportive data for the benefit of NK1R antagonists in patients receiving moderately emetogenic carboplatin-containing chemotherapy [<a href="#rid48">48-51,118,119</a>]. (See <a class="local">'Neurokinin-1 receptor antagonists'</a> above.)</p><p class="headingAnchor" id="H3539521766"><span class="h3">Non-carboplatin-containing regimens</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">Aprepitant</a> – In contrast to carboplatin-containing regimens, there are conflicting data on the benefit of adding an NK1R antagonist for moderately emetogenic non-carboplatin-based regimens:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The relative roles of <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> and <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> in controlling delayed nausea were studied in a randomized trial of 944 evaluable patients receiving primarily (95 percent) moderately emetogenic chemotherapy (<a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="8663" href="/z/d/drug information/8663.html" rel="external">epirubicin</a>, <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>, or <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>) [<a href="#rid120">120</a>]. Palonosetron did not provide superior control of delayed nausea compared with <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">granisetron</a> when both were provided on day 1 with <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> and when <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">prochlorperazine</a> was administered on days 2 and 3. In addition, aprepitant was not more effective than prochlorperazine when both were combined with dexamethasone on days 2 and 3.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>On the other hand, a benefit for adding <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> (125 mg day 1, 80 mg daily on days 2 and 3) to <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> was shown in a randomized Chinese trial limited to a population of patients with multiple risk factors for emesis (exclusively female, all &lt;50 years of age, history of limited ethanol consumption, and two-thirds nonchemotherapy naïve). The trial included 248 patients receiving short-term infusional <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> plus <a class="drug drug_general" data-topicid="9548" href="/z/d/drug information/9548.html" rel="external">leucovorin</a>, and either <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> (FOLFOX) or <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> (FOLFIRI) chemotherapy for gastrointestinal cancer [<a href="#rid121">121</a>]. The complete response rate was significantly higher in the aprepitant group (87 versus 67 percent), and the benefits were seen both in the acute and delayed phases of the trial. Given the unique nature of the patient population with regards to risk factors for emesis, it is difficult to extrapolate the findings to a general population receiving these chemotherapy regimens.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A year 2018 meta-analysis of 16 trials of moderately emetogenic chemotherapy (that did not include the Chinese trial) concluded that there was clear benefit for the addition of a NK1R antagonist for carboplatin-based chemotherapy but not globally for all moderately emetogenic regimens, including those containing <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> [<a href="#rid119">119</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other strategies</strong> – For patients receiving other moderately emetogenic regimens with a risk of delayed emesis, glucocorticoids are consistently useful agents:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The value of maintenance <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> was demonstrated in a randomized, placebo-controlled trial of patients undergoing cyclophosphamide-based chemotherapy [<a href="#rid102">102</a>]. In this trial, 98 patients were given <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">granisetron</a> and dexamethasone before chemotherapy and randomized to receive oral dexamethasone 4 mg twice daily either as maintenance or no maintenance. Maintenance dexamethasone was associated with a higher rate of complete (57 versus 33 percent) and major control (33 versus 15 percent) of delayed emesis. No trials have examined the benefit of maintenance dexamethasone in patients treated with <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> who have received an NK1R antagonist.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The 5-HT3 receptor antagonists also have activity as single agents for delayed emesis with cyclophosphamide-based chemotherapy [<a href="#rid23">23</a>]. However, there is no evidence that they are superior to <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> alone or that combination therapy with dexamethasone is superior to dexamethasone alone [<a href="#rid104">104,105</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A randomized trial of 708 patients receiving moderately emetogenic chemotherapy and concurrent antiemetics illustrates the relative roles of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> and 5-HT3 receptor antagonists in the management of delayed emesis [<a href="#rid104">104</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Patients without acute nausea or vomiting (the low-risk group) were randomized to receive <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (4 mg orally, twice daily on days 2 through 5) plus <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> (8 mg orally, twice daily on days 2 through 5), dexamethasone alone on the same schedule, or a placebo. Among these 618 patients, there was a complete absence of delayed nausea and vomiting in 92, 87, and 77 percent of patients in the combined therapy, dexamethasone, and placebo groups, respectively. Protection with dexamethasone alone or with dexamethasone plus ondansetron was better than that with placebo; however, the combination was not statistically superior to dexamethasone alone. Results according to the different moderately emetogenic agents were not provided.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>The key factor in preventing delayed emesis was the control of acute symptoms following chemotherapy. Patients who had either vomiting or moderate to severe nausea in the 24 hours following chemotherapy constituted a high-risk group. These 87 patients were randomly assigned to oral <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> alone or in combination with <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a>, at the same doses and schedules as in the low-risk group. Despite treatment, complete protection from delayed emesis or moderate to severe nausea was achieved in only 41 and 23 percent of patients treated with the combination and dexamethasone, respectively.</p><p></p><p class="headingAnchor" id="H1582722570"><span class="h1">ANTICIPATORY EMESIS</span><span class="headingEndMark"> — </span>The primary approach to the prevention of anticipatory emesis is the prevention of CINV beginning with the initial cycles of chemotherapy. For patients who do develop anticipatory emesis, we suggest behavioral therapy and/or benzodiazepines. These recommendations are in keeping with guidelines from the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO)/Multinational Association of Supportive Care in Cancer (MASCC) [<a href="#rid4">4,7,122</a>]. </p><p>Anticipatory nausea and emesis are conditioned responses that occur in patients who experienced severe nausea and vomiting during prior cycles of chemotherapy [<a href="#rid123">123</a>], and that appear to be induced by sensory cues and cognitive anticipation of subsequent chemotherapy. Anticipatory nausea has also been described among patients who have a high expectation of developing nausea despite never having received chemotherapy [<a href="#rid124">124</a>]. Anticipatory nausea is more commonly reported than is anticipatory emesis (14 versus 1 to 2 percent in one study [<a href="#rid125">125</a>]). </p><p>The most effective means to prevent anticipatory nausea or emesis is to ensure good control of acute and delayed emesis, starting from the initial chemotherapy cycle  (<a class="graphic graphic_table graphicRef72865" href="/z/d/graphic/72865.html" rel="external">table 3</a>). Once anticipatory emesis has been established, nonpharmacologic methods (eg, hypnosis, behavioral therapy with systemic desensitization) may be effective [<a href="#rid126">126-128</a>]. (See  <a class="medical medical_review" href="/z/d/html/2831.html" rel="external">"Overview of complementary, alternative, and integrative medicine practices in oncology care, and potential risks and harm"</a>.)</p><p>Although few formal trials have been carried out, benzodiazepines before and during chemotherapy may be useful [<a href="#rid129">129-131</a>]. In one double-blind trial of 57 women undergoing adjuvant chemotherapy for primary breast cancer, for example, the addition of low-dose <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">alprazolam</a> (0.5 to 2 mg/day) to a psychologic support program including progressive relaxation training was associated with a significantly reduced rate of anticipatory nausea compared with placebo (0 versus 18 percent) [<a href="#rid130">130</a>].</p><p class="headingAnchor" id="H4204415522"><span class="h1">SPECIAL SITUATIONS</span></p><p class="headingAnchor" id="H25"><span class="h2">Consecutive-day intravenous therapy with highly emetogenic agents</span><span class="headingEndMark"> — </span>For patients receiving four to five days of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, such as in regimens for testicular or ovarian germ cell cancer, we suggest the use of a daily dose of a first-generation type three 5-hydroxytryptamine (5-HT3) receptor antagonist, or a single application of a <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">granisetron</a> transdermal patch or <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> on days 1, 3, and 5 plus daily <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, with the addition of <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> (days 1, 2, and 3) or another neurokinin-1 receptor (NK1R) antagonist (<a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">fosaprepitant</a>, netupitant plus palonosetron [NEPA], or <a class="drug drug_general" data-topicid="103785" href="/z/d/drug information/103785.html" rel="external">rolapitant</a>) on day 1 for highly emetogenic regimens.</p><p>When moderately emetogenic chemotherapy agents are administered on several consecutive days, prophylaxis is more difficult. This may be due to anticipatory emesis on the subsequent days of therapy or to the compounding of acute and delayed effects of treatment. American Society of Clinical Oncology (ASCO) antiemetic guidelines suggest that antiemetics appropriate for the emetogenic risk class of the chemotherapy be administered for each day of the chemotherapy and for two days afterward, if appropriate [<a href="#rid7">7</a>].</p><p>Trials conducted before the availability of NK1R antagonists suggested that repetitive daily dosing with a 5-HT3 receptor antagonist combined with <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> was the best approach [<a href="#rid132">132,133</a>]. However, the benefit of adding <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> to a 5-HT3 antagonist and dexamethasone was shown in small trial of patients receiving a five consecutive day cisplatin-containing chemotherapy regimen for germ cell cancer [<a href="#rid134">134</a>]. All patients received a 5-HT3 antagonist (other than <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a>) once daily on days 1 through 5 plus dexamethasone 20 mg once daily on days 1 and 2, and were randomly assigned to aprepitant (125 mg on day 3, 80 mg on days 4 and 5) or no aprepitant. The group receiving aprepitant also received dexamethasone 4 mg twice daily on days 6, 7, and 8, while the placebo group received dexamethasone 8 mg twice daily on days 6 and 7, and 4 mg twice daily on day 8. A complete response (no emetic episodes and no use of rescue medication) was noted in significantly more patients receiving aprepitant (42 versus 13 percent), and the visual analog scale (VAS) score for nausea was numerically lower for aprepitant, although the difference compared with placebo was not statistically significant.</p><p>Whether a similar degree of protection can be gained by substituting one day of <a class="drug drug_general" data-topicid="9032" href="/z/d/drug information/9032.html" rel="external">fosaprepitant</a> for three days of <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> is not clear. A phase II study conducted by the Hoosier Oncology Group in 65 patients receiving a five-day chemotherapy regimen for germ cell cancer reported a lower than expected rate of complete response (13 of 51 assessable patients, 24 percent) [<a href="#rid135">135</a>]. Although the authors provided a rationale for starting the NK1R on day 3 rather than on day 1, the optimal schedule for NK1R antagonists for patients receiving consecutive-day therapy with highly emetogenic chemotherapy is unknown, given the lack of comparative trials addressing this question. </p><p class="headingAnchor" id="H26"><span class="h3">Granisetron transdermal patch</span><span class="headingEndMark"> — </span>A transdermal preparation of <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">granisetron</a> is available (Sancuso) that contains 34.3 mg of granisetron and is designed to deliver 3.1 mg of the drug every 24 hours for up to seven days. The efficacy of the granisetron patch relative to daily oral administration of granisetron has been addressed in three trials [<a href="#rid136">136-138</a>], all of which showed no significant inferiority of transdermal administration.</p><p></p><p>The largest trial was a multinational, randomized, double-blind, double-dummy controlled trial in which 641 patients receiving the first cycle of a multiday regimen of either moderately or highly emetogenic chemotherapy were randomly assigned to the patch (applied 24 to 48 hours before the first day of chemotherapy) plus a placebo capsule or to oral <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">granisetron</a> (2 mg daily, one hour prior to chemotherapy on each day of chemotherapy administration) plus a placebo patch [<a href="#rid136">136</a>]. Concurrent glucocorticoids, which were administered at the investigator's discretion, were given to approximately 70 percent of the patients in each arm.</p><p>The percentage of patients who had complete control of nausea and vomiting until 24 hours after the last chemotherapy dose was not significantly worse with the transdermal patch (60 versus 65 percent with oral <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">granisetron</a>). Fewer than 1 percent of the patches became detached during treatment. In both groups, the most commonly reported toxicities were constipation and headache.</p><p>Based upon this trial, the <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">granisetron</a> transdermal system was approved in the United States for the prevention of CINV in patients receiving multiday, moderately or highly emetogenic, intravenous chemotherapy for up to five consecutive days. It is recommended that the patch be applied to the upper outer arm a minimum of 24 hours before chemotherapy and removed 24 hours or more after the last chemotherapy dose is administered. It can be worn for up to seven days, depending on the duration of the chemotherapy regimen [<a href="#rid139">139,140</a>].</p><p class="headingAnchor" id="H1044202"><span class="h2">Induction therapy for acute leukemia</span><span class="headingEndMark"> — </span>High-dose <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">cytarabine</a> regimens (in which cytarabine is administered daily for five or seven days, often with an anthracycline) are the cornerstone of treatment for acute myeloid leukemia (AML). Few studies have addressed the issue of CINV and optimal prophylaxis in this setting [<a href="#rid38">38,141,142</a>]. Although data are lacking, a daily dose of a 5-HT3 receptor antagonist (eg, <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> 16 mg) with or without <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> appears to be a reasonable option in this setting.</p><p class="headingAnchor" id="H27"><span class="h2">High-dose chemotherapy regimens</span><span class="headingEndMark"> — </span>For patients receiving high-dose chemotherapy with hematopoietic cell transplantation (HCT), we recommend a combination of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, a 5-HT3 receptor antagonist, and an NK1R antagonist. A four-drug combination of dexamethasone, a 5-HT3 receptor antagonist, an NK1R antagonist, and <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> is another option for patients undergoing high-dose chemotherapy with HCT.</p><p>The use of high-dose chemotherapy in association with a bone marrow or peripheral blood stem cell transplant presents a special challenge to achieving good antiemetic control. The chemotherapy agents employed are often of moderate to high emetogenic risk.</p><p>In addition, there are a number of potential factors that can contribute to an increased incidence and severity of CINV in this setting:</p><p class="bulletIndent1"><span class="glyph">●</span>Higher doses of chemotherapy</p><p class="bulletIndent1"><span class="glyph">●</span>Consecutive-day administration</p><p class="bulletIndent1"><span class="glyph">●</span>Prior treatment with chemotherapy</p><p class="bulletIndent1"><span class="glyph">●</span>Inclusion of radiation therapy (especially total body irradiation), which has high emetogenic risk</p><p class="bulletIndent1"><span class="glyph">●</span>Associated other medical conditions or medications that may cause emesis</p><p></p><p>There are a limited number of randomized trials specifically studying the issue of emesis in the high-dose chemotherapy setting with HCT [<a href="#rid143">143-147</a>]. Most studies have focused on the combination of a 5-HT3 receptor antagonist and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> [<a href="#rid148">148-151</a>]. However, a role for <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> in this setting is supported by two phase III trials:</p><p class="bulletIndent1"><span class="glyph">●</span>In one trial, 181 patients undergoing a preparative regimen for hematopoietic stem cell transplantation were randomly assigned to <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> and either <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> or placebo [<a href="#rid152">152</a>]. Significantly better emetic control was noted in patients who received aprepitant (no emesis for the entire study period in 73 versus 23 percent of the placebo group), although there were no differences between the groups in use of rescue antiemetics.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Benefit for <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> was also noted in a second phase III trial in which 362 patients with multiple myeloma undergoing autologous HCT after high-dose <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a> were randomly assigned to <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">granisetron</a> plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> and either aprepitant or placebo [<a href="#rid153">153</a>]. Significantly more patients receiving aprepitant achieved the primary endpoint (no emesis and no need for rescue therapy within 120 hours of administration of high-dose melphalan, 58 versus 41 percent, p = 0.00042). Absence of major nausea (94 versus 88 percent) and emesis (78 versus 65 percent) within 120 hours also favored the aprepitant group.</p><p></p><p>Additional benefit for the addition of <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> to this three-drug regimen was suggested in a randomized placebo-controlled trial conducted in a trial of 98 patients undergoing high-dose chemotherapy plus HCT for a hematologic malignancy. Olanzapine 10 mg or a matching placebo was administered on each chemotherapy day and for three days after [<a href="#rid147">147</a>]. Rates of complete antiemetic response were significantly higher with olanzapine in overall (55 versus 26 percent) and delayed (61 versus 30 percent) phases, but not in the acute phase. Furthermore, significantly more patients receiving olanzapine achieved no more than minimal nausea in the overall and delayed phases. Results were significant in the autologous but not the allogeneic cohorts. None of the patients receiving olanzapine discontinued therapy for adverse events.</p><p>The updated 2020 antiemetic guidelines from ASCO and the 2016 <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmascc.org%2Fresources%2Fmascc-guidelines%2F&amp;token=795%2BxPqISNblxEq%2B8WXBBjoU8Peh%2FAysEk%2FPCZ98NtpEW3K8qd7SLaghSimhgt0C&amp;TOPIC_ID=1151" target="_blank">Multinational Association of Supportive Care in Cancer (MASCC)/European Society for Medical Oncology (ESMO)</a> guidelines recommend a 5-HT3 receptor antagonist plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> with consideration of <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">aprepitant</a> in this setting [<a href="#rid7">7,154</a>]. However, updated 2020 ASCO guidelines suggest that clinicians may also offer a four-drug regimen in this setting, with a 5-HT3 receptor antagonist plus dexamethasone, an NK1R antagonist, and <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H250318230"><span class="h2">Oral chemotherapy</span><span class="headingEndMark"> — </span>A severe limitation of current recommendations for prevention and treatment of CINV is the lack of guidance for patients receiving oral chemotherapy agents, which vary in their emetogenicity potential  (<a class="graphic graphic_table graphicRef65923" href="/z/d/graphic/65923.html" rel="external">table 2</a>). Virtually all of the clinical trials evaluating prevention and treatment of CINV have focused on intravenously delivered chemotherapy. Therefore, evidenced-based guidelines for antiemetic prophylaxis with oral chemotherapy agents are not currently possible. Consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) recommend the following approach: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>High/moderate emetic risk agents</strong> – An orally administered 5-HT3 antagonist starting before chemotherapy and continuing daily. Options include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8592" href="/z/d/drug information/8592.html" rel="external">Dolasetron</a> 100 mg daily</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">Ondansetron</a> 8 to 16 mg daily</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">Granisetron</a> 1 to 2 mg orally daily or a granisetron transdermal patch every seven days </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low/minimal emetic risk agents</strong> – Treat only on an "as needed" basis. For patients who develop nausea/emesis during treatment, options include <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a> (10 to 20 mg orally, every six hours), <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">prochlorperazine</a> (10 mg orally, every six hours), <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">haloperidol</a> (1 to 2 mg orally, every four to six hours), or a daily dose of a 5-HT3 antagonist (eg, <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">ondansetron</a> 8 to 16 mg, <a class="drug drug_general" data-topicid="8592" href="/z/d/drug information/8592.html" rel="external">dolasetron</a> 100 mg, or <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">granisetron</a> 1 to 2 mg), as needed.</p><p></p><p class="headingAnchor" id="H1096056860"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116116.html" rel="external">"Society guideline links: Chemotherapy-induced nausea and vomiting in adults"</a>.)</p><p class="headingAnchor" id="H5788060"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16303.html" rel="external">"Patient education: Nausea and vomiting with cancer treatment (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H31"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General aspects</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chemotherapy-induced nausea and vomiting (CINV) is an important adverse effect of treatment. The most important factor determining the likelihood of acute or delayed emesis developing is the intrinsic emetogenicity of a particular chemotherapy agent  (<a class="graphic graphic_table graphicRef58756" href="/z/d/graphic/58756.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef65923" href="/z/d/graphic/65923.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/1150.html" rel="external">"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting", section on 'Chemotherapy agent'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The four categories of drugs with the highest therapeutic index for the management of CINV are the type three 5-hydroxytryptamine (5-HT3) receptor antagonists, the neurokinin-1 receptor (NK1R) antagonists, glucocorticoids (especially <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>), and the antipsychotic medication <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> when used in combination with other antiemetics. (See <a class="local">'5-HT3 receptor antagonists'</a> above and <a class="local">'Neurokinin-1 receptor antagonists'</a> above and <a class="local">'Glucocorticoids'</a> above and <a class="local">'Olanzapine'</a> above.)</p><p></p><p class="bulletIndent2">These agents are used alone and/or in combinations, depending on the specific chemotherapy regimen being administered, as recommended in the American Society of Clinical Oncology (ASCO) and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmascc.org%2Fresources%2Fmascc-guidelines%2F&amp;token=795%2BxPqISNblxEq%2B8WXBBjoU8Peh%2FAysEk%2FPCZ98NtpEW3K8qd7SLaghSimhgt0C&amp;TOPIC_ID=1151" target="_blank">Multinational Association of Supportive Care in Cancer (MASCC)/European Society for Medical oncology (ESMO)</a> guidelines. (See <a class="local">'Antiemetic efficacy of individual agents'</a> above.)</p><p></p><p class="bulletIndent2">Electrocardiogram (ECG) interval changes are a class effect of the first-generation 5-HT3 receptor antagonists; avoid use in patients with congenital long QT syndrome. Abnormal potassium and magnesium levels should be corrected before initiation of treatment. ECG monitoring is recommended in patients with underlying cardiac disease, and with concurrent use of other medications that predispose to QTc prolongation  (<a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">table 4</a>). (See <a class="local">'Cardiac issues'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Our recommendations for antiemetic prophylaxis for intravenously administered chemotherapy agents, which largely parallel those of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fmascc.org%2Fresources%2Fmascc-guidelines%2F&amp;token=795%2BxPqISNblxEq%2B8WXBBjoU8Peh%2FAysEk%2FPCZ98NtpEW3K8qd7SLaghSimhgt0C&amp;TOPIC_ID=1151" target="_blank">MASCC/ESMO</a> and ASCO, are outlined in the table  (<a class="graphic graphic_table graphicRef72865" href="/z/d/graphic/72865.html" rel="external">table 3</a>) and summarized in the following bullets:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Highly emetogenic regimens</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients receiving <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and other highly emetogenic agents  (<a class="graphic graphic_table graphicRef58756" href="/z/d/graphic/58756.html" rel="external">table 1</a>), we recommend antiemetic therapy with a combination of a 5-HT3 receptor antagonist, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, and an NK1R antagonist (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). We also suggest the addition of <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Highly emetogenic chemotherapy'</a> above and <a class="local">'Need for a 5-HT3 agent'</a> above and <a class="local">'Olanzapine'</a> above.)</p><p></p><p class="bulletIndent2">Details of the regimen are described above. (See <a class="local">'Highly emetogenic chemotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients receiving an anthracycline plus <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> for breast cancer, we use a similar regimen <strong>except</strong> we suggest not using <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> on days 2 to 4 (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'NK1R antagonist plus dexamethasone and 5-HT3 antagonist'</a> above and <a class="local">'Olanzapine'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For non-breast cancer populations receiving an anthracycline plus <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> regimen, this prophylactic regimen is also reasonable. However, for patients who are receiving anthracycline/cyclophosphamide regimens that incorporate glucocorticoids (eg, for non-Hodgkin lymphoma), day 1 <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> alone, without the use of an NK1R antagonist or <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>, is an acceptable option. (See <a class="local">'Other diseases'</a> above and <a class="local">'Palonosetron'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderately emetogenic regimens</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients receiving carboplatin-based regimens, we recommend the combination of an NK1R antagonist, a 5-HT3 receptor antagonist, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> on day 1 (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Moderately emetogenic chemotherapy'</a> above and <a class="local">'Neurokinin-1 receptor antagonists'</a> above.)</p><p></p><p class="bulletIndent2">Additional prophylaxis beyond day 1 for delayed emesis is not needed for most patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients receiving non-carboplatin-based regimens with a moderate risk for CINV  (<a class="graphic graphic_table graphicRef58756" href="/z/d/graphic/58756.html" rel="external">table 1</a>), we recommend a 5-HT3 receptor antagonist plus <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> on day 1 (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>).</p><p></p><p class="bulletIndent2">To prevent delayed emesis, we suggest single-agent <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> on days 2 and 3 (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>) if a first-generation 5-HT3 receptor antagonist is used on day 1. Treatment with a first-generation 5-HT3 receptor antagonist alone on days 2 and 3 is a reasonable alternative. If <a class="drug drug_general" data-topicid="9944" href="/z/d/drug information/9944.html" rel="external">palonosetron</a> is used on day 1, additional prophylaxis beyond day 1 is not needed for most patients. (See <a class="local">'Moderate-risk regimens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low and minimal risk regimens</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients receiving low emetic risk agents  (<a class="graphic graphic_table graphicRef58756" href="/z/d/graphic/58756.html" rel="external">table 1</a>), we suggest <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (4 to 8 mg) as a single agent (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). If glucocorticoid use is contraindicated or undesirable (eg, with the use of long-term weekly chemotherapy) alternative approaches include a single dose of a phenothiazine-type drug, such as <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">prochlorperazine</a> or <a class="drug drug_general" data-topicid="10147" href="/z/d/drug information/10147.html" rel="external">levomepromazine</a>; a single dose of a 5-HT3 antagonist; or <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a>. (See <a class="local">'Glucocorticoids'</a> above and <a class="local">'Other agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients receiving chemotherapy agents with a minimal risk of causing emesis  (<a class="graphic graphic_table graphicRef58756" href="/z/d/graphic/58756.html" rel="external">table 1</a>), we suggest that antiemetic therapy <strong>not</strong> be routinely administered to prevent either acute or delayed CINV (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Prophylactic antiemetics (<a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> 4 to 8 mg, <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">prochlorperazine</a>, <a class="drug drug_general" data-topicid="10147" href="/z/d/drug information/10147.html" rel="external">levomepromazine</a>, or <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">metoclopramide</a>) may be administered to patients who have had emesis with prior low-risk regimens, or on an "as needed" basis. (See  <a class="medical medical_review" href="/z/d/html/1150.html" rel="external">"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting", section on 'Chemotherapy agent'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For adult patients, the addition of an immune checkpoint inhibitor (ICI) to cytotoxic chemotherapy does not change the principle of choosing the antiemetic regimen based on the emetogenicity of the agents administered, including the use of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>. ICIs administered either alone or in combination with other ICIs are minimally emetogenic and do not require the use of a prophylactic antiemetic. (See <a class="local">'Immune checkpoint inhibitor immunotherapy'</a> above and <a class="local">'Patients receiving immune checkpoint inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Special situations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anticipatory emesis</strong> – The primary approach to the prevention of anticipatory emesis is the prevention of CINV beginning with the initial cycles of chemotherapy. For patients who do develop anticipatory emesis, we suggest behavioral therapy and/or benzodiazepines (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Anticipatory emesis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients undergoing hematopoietic cell transplantation</strong> – For patients receiving high-dose intravenous chemotherapy with hematopoietic cell transplantation, we suggest a combination of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, a 5-HT3 receptor antagonist, and an NK1R antagonist (<a class="grade" href="https:///uptodate/show/grade_4" rel="external">Grade 2A</a>). The addition of <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> to this regimen is another option. (See <a class="local">'High-dose chemotherapy regimens'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Multiday regimens</strong> – For patients receiving four or five consecutive days of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> in regimens for testicular or ovarian germ cell cancer, we suggest a daily dose of an oral 5-HT3 receptor antagonist or a <a class="drug drug_general" data-topicid="8501" href="/z/d/drug information/8501.html" rel="external">granisetron</a> transdermal patch plus daily <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, with the addition of an NK1R antagonist on day 1 (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Multiday regimens'</a> above and <a class="local">'Consecutive-day intravenous therapy with highly emetogenic agents'</a> above.)</p><p></p><p class="bulletIndent2">Prophylaxis is more difficult for moderately emetogenic chemotherapy agents administered on several consecutive days. We agree with ASCO guidelines, which suggest antiemetics appropriate for the emetogenic risk class of the chemotherapy on each day of the chemotherapy and for two days after, if appropriate. (See <a class="local">'Consecutive-day intravenous therapy with highly emetogenic agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oral agents</strong> – Oral chemotherapy agents have a variable emetogenicity potential  (<a class="graphic graphic_table graphicRef65923" href="/z/d/graphic/65923.html" rel="external">table 2</a>), and there is no consensus as to the appropriate prophylactic antiemetic strategy. We agree with consensus-based guidelines from NCCN (see <a class="local">'Oral chemotherapy'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>High/moderate-risk agents</strong> – A 5-HT3 antagonist starting before chemotherapy and continuing daily.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Low/minimal-risk agents</strong> – Treat only on an "as needed" basis.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15:103.</a></li><li><a class="nounderline abstract_t">Roila F, Hesketh PJ, Herrstedt J, Antiemetic Subcommitte of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006; 17:20.</a></li><li><a class="nounderline abstract_t">Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011; 29:4189.</a></li><li><a class="nounderline abstract_t">Hesketh PJ, Bohlke K, Lyman GH, et al. Antiemetics: American Society of Clinical Oncology Focused Guideline Update. J Clin Oncol 2016; 34:381.</a></li><li><a class="nounderline abstract_t">Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016; 27:v119.</a></li><li><a class="nounderline abstract_t">Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017; 35:3240.</a></li><li><a class="nounderline abstract_t">Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020; 38:2782.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Di Renzo N, Montanini A, Mannina D, et al. Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL). Support Care Cancer 2011; 19:1505.</a></li><li><a class="nounderline abstract_t">Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008; 358:2482.</a></li><li><a class="nounderline abstract_t">Heron JF, Goedhals L, Jordaan JP, et al. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group. Ann Oncol 1994; 5:579.</a></li><li><a class="nounderline abstract_t">Chevallier B. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group. Eur J Cancer 1990; 26 Suppl 1:S33.</a></li><li><a class="nounderline abstract_t">Warr D, Wilan A, Venner P, et al. A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial. Eur J Cancer 1992; 29A:33.</a></li><li><a class="nounderline abstract_t">Chevallier B, Cappelaere P, Splinter T, et al. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. Support Care Cancer 1997; 5:22.</a></li><li><a class="nounderline abstract_t">Endo J, Iihara H, Yamada M, et al. A randomized controlled non-inferiority study comparing the antiemetic effect between intravenous granisetron and oral azasetron based on estimated 5-HT3 receptor occupancy. Anticancer Res 2012; 32:3939.</a></li><li><a class="nounderline abstract_t">Davidson N, Rapoport B, Erikstein B, et al. Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emesis Study Group. Clin Ther 1999; 21:492.</a></li><li><a class="nounderline abstract_t">del Giglio A, Soares HP, Caparroz C, Castro PC. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer 2000; 89:2301.</a></li><li><a class="nounderline abstract_t">Gandara DR, Roila F, Warr D, et al. Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration. Support Care Cancer 1998; 6:237.</a></li><li><a class="nounderline abstract_t">Seynaeve C, Schuller J, Buser K, et al. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group. Br J Cancer 1992; 66:192.</a></li><li><a class="nounderline abstract_t">Beck TM, Hesketh PJ, Madajewicz S, et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol 1992; 10:1969.</a></li><li><a class="nounderline abstract_t">Ettinger DS, Eisenberg PD, Fitts D, et al. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Cancer 1996; 78:144.</a></li><li><a class="nounderline abstract_t">Harman GS, Omura GA, Ryan K, et al. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Cancer Chemother Pharmacol 1996; 38:323.</a></li><li><a class="nounderline abstract_t">Kaizer L, Warr D, Hoskins P, et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994; 12:1050.</a></li><li><a class="nounderline abstract_t">Perez EA, Hesketh P, Sandbach J, et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 1998; 16:754.</a></li><li><a class="nounderline abstract_t">Gralla RJ, Navari RM, Hesketh PJ, et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 1998; 16:1568.</a></li><li><a class="nounderline abstract_t">Mason JW, Selness DS, Moon TE, et al. Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron. Clin Cancer Res 2012; 18:2913.</a></li><li><a class="nounderline abstract_t">Mason JW, Moon TE, O'Boyle E, Dietz A. A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation. Cancer Manag Res 2014; 6:181.</a></li><li><a class="nounderline abstract_t">Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother 2003; 37:1276.</a></li><li><a class="nounderline abstract_t">Pinarli FG, Elli M, Dagdemir A, et al. Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer. Pediatr Blood Cancer 2006; 47:567.</a></li><li><a class="nounderline abstract_t">Keller GA, Ponte ML, Di Girolamo G. Other drugs acting on nervous system associated with QT-interval prolongation. Curr Drug Saf 2010; 5:105.</a></li><li><a class="nounderline abstract_t">Turner S, Mathews L, Pandharipande P, Thompson R. Dolasetron-induced torsades de pointes. J Clin Anesth 2007; 19:622.</a></li><li class="breakAll">US Food and Drug Administration (FDA). FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron. http://www.fda.gov/Drugs/DrugSafety/ucm310190.htm (Accessed on July 02, 2012).</li><li><a class="nounderline abstract_t">Havrilla PL, Kane-Gill SL, Verrico MM, et al. Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. Ann Pharmacother 2009; 43:532.</a></li><li class="breakAll">US Food and Drug Administration (FDA). FDA Drug Safety Communication: Abnormal heart rhythms associated with use of dolasetron mesylate. http://www.fda.gov/Drugs/DrugSafety/ucm237081.htm (Accessed on December 21, 2010).</li><li class="breakAll">Health Canada. Zofran (ondansetron) - Dosage and Administration of Intravenous Ondansetron in Geriatrics (&gt;65 years of age) - For Health Professionals. 2014. Available at: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/39943a-eng.php (Accessed on June 16, 2014).</li><li><a class="nounderline abstract_t">Gonullu G, Demircan S, Demirag MK, et al. Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer 2012; 20:1435.</a></li><li><a class="nounderline abstract_t">Morganroth J, Flaharty KK, Parisi S, Moresino C. Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers. Support Care Cancer 2016; 24:621.</a></li><li><a class="nounderline abstract_t">Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98:2473.</a></li><li><a class="nounderline abstract_t">Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14:1570.</a></li><li><a class="nounderline abstract_t">Likun Z, Xiang J, Yi B, et al. A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. Oncologist 2011; 16:207.</a></li><li><a class="nounderline abstract_t">Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009; 10:115.</a></li><li><a class="nounderline abstract_t">Aapro MS, Grunberg SM, Manikhas GM, et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006; 17:1441.</a></li><li><a class="nounderline abstract_t">Kubota K, Saito M, Aogi K, et al. Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens. Support Care Cancer 2016; 24:4025.</a></li><li><a class="nounderline abstract_t">Suzuki K, Yamanaka T, Hashimoto H, et al. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Ann Oncol 2016; 27:1601.</a></li><li><a class="nounderline abstract_t">Okada Y, Oba K, Furukawa N, et al. One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis. Oncologist 2019; 24:1593.</a></li><li><a class="nounderline abstract_t">Komatsu Y, Okita K, Yuki S, et al. Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron. Cancer Sci 2015; 106:891.</a></li><li class="breakAll">WHO Pharmaceuticals newsletter. Ondansetron and serotonin syndrome. 2012; 3:16. Available at: https://www.who.int/medicines/publications/Newsletter_3_2012.pdf.</li><li><a class="nounderline abstract_t">Hesketh PJ, Schnadig ID, Schwartzberg LS, et al. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer 2016; 122:2418.</a></li><li><a class="nounderline abstract_t">Tanioka M, Kitao A, Matsumoto K, et al. A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer 2013; 109:859.</a></li><li><a class="nounderline abstract_t">Yahata H, Kobayashi H, Sonoda K, et al. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol 2016; 21:491.</a></li><li><a class="nounderline abstract_t">Ito Y, Karayama M, Inui N, et al. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. Lung Cancer 2014; 84:259.</a></li><li><a class="nounderline abstract_t">Hesketh PJ, Wright O, Rosati G, et al. Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. Support Care Cancer 2012; 20:1471.</a></li><li><a class="nounderline abstract_t">Nishimura J, Satoh T, Fukunaga M, et al. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer 2015; 51:1274.</a></li><li><a class="nounderline abstract_t">Zhang Y, Yang Y, Zhang Z, et al. Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis. J Natl Cancer Inst 2017; 109.</a></li><li><a class="nounderline abstract_t">dos Santos LV, Souza FH, Brunetto AT, et al. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst 2012; 104:1280.</a></li><li><a class="nounderline abstract_t">Campos D, Pereira JR, Reinhardt RR, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001; 19:1759.</a></li><li><a class="nounderline abstract_t">Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. J Clin Oncol 2011; 29:1495.</a></li><li><a class="nounderline abstract_t">Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 2014; 25:1340.</a></li><li><a class="nounderline abstract_t">Gralla RJ, Bosnjak SM, Hontsa A, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 2014; 25:1333.</a></li><li><a class="nounderline abstract_t">Zhang L, Lu S, Feng J, et al. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Ann Oncol 2018; 29:452.</a></li><li><a class="nounderline abstract_t">Aapro M, Karthaus M, Schwartzberg L, et al. NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Support Care Cancer 2017; 25:1127.</a></li><li><a class="nounderline abstract_t">Hata A, Okamoto I, Inui N, et al. Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE. J Clin Oncol 2022; 40:180.</a></li><li><a class="nounderline abstract_t">Matsuura K, Tsurutani J, Inoue K, et al. A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC. Cancer 2022; 128:1692.</a></li><li><a class="nounderline abstract_t">Schwartzberg L, Roeland E, Andric Z, et al. Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Ann Oncol 2018; 29:1535.</a></li><li><a class="nounderline abstract_t">Sugawara S, Inui N, Kanehara M, et al. Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Cancer 2019; 125:4076.</a></li><li><a class="nounderline abstract_t">Schwartzberg LS, Modiano MR, Rapoport BL, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol 2015; 16:1071.</a></li><li><a class="nounderline abstract_t">Rapoport BL, Chasen MR, Gridelli C, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol 2015; 16:1079.</a></li><li class="breakAll">US Food and Drug Administration (FDA). FDA postmarked drug safety information for patients and providers. Rolapitant injectable emulsion. https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm592465.htm?et_cid=39940459&amp;et_rid=907466112&amp;linkid=letter+to+health+care+providers (Accessed on January 17, 2018).</li><li><a class="nounderline abstract_t">McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003; 74:17.</a></li><li><a class="nounderline abstract_t">Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21:4112.</a></li><li><a class="nounderline abstract_t">Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97:3090.</a></li><li><a class="nounderline abstract_t">Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005; 23:2822.</a></li><li><a class="nounderline abstract_t">Nygren P, Hande K, Petty KJ, et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol 2005; 55:609.</a></li><li><a class="nounderline abstract_t">Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol 2000; 18:3409.</a></li><li><a class="nounderline abstract_t">Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995; 332:1.</a></li><li><a class="nounderline abstract_t">Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991; 9:675.</a></li><li><a class="nounderline abstract_t">Smyth JF, Coleman RE, Nicolson M, et al. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? BMJ 1991; 303:1423.</a></li><li><a class="nounderline abstract_t">Hesketh PJ, Harvey WH, Harker WG, et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 1994; 12:596.</a></li><li><a class="nounderline abstract_t">Joss RA, Bacchi M, Buser K, et al. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1994; 5:253.</a></li><li><a class="nounderline abstract_t">Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019; 394:1929.</a></li><li><a class="nounderline abstract_t">Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 2018; 379:2040.</a></li><li><a class="nounderline abstract_t">West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019; 20:924.</a></li><li><a class="nounderline abstract_t">Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research. J Clin Oncol 1998; 16:2937.</a></li><li><a class="nounderline abstract_t">Italian Group For Antiemetic Research. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide:. J Clin Oncol 2004; 22:725.</a></li><li><a class="nounderline abstract_t">Sutherland A, Naessens K, Plugge E, et al. Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults. Cochrane Database Syst Rev 2018; 9:CD012555.</a></li><li><a class="nounderline abstract_t">Yokoe T, Hayashida T, Nagayama A, et al. Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis. Oncologist 2019; 24:e347.</a></li><li><a class="nounderline abstract_t">Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 2016; 375:134.</a></li><li class="breakAll">P Hesketh, personal communication, 07/2016.</li><li><a class="nounderline abstract_t">Yanai T, Iwasa S, Hashimoto H, et al. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol 2018; 23:382.</a></li><li><a class="nounderline abstract_t">Ithimakin S, Theeratrakul P, Laocharoenkiat A, et al. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. Support Care Cancer 2020; 28:5335.</a></li><li><a class="nounderline abstract_t">Hashimoto H, Abe M, Tokuyama O, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020; 21:242.</a></li><li><a class="nounderline abstract_t">Chow R, Herrstedt J, Aapro M, et al. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer 2021; 29:3439.</a></li><li><a class="nounderline abstract_t">Chow R, Navari RM, Terry B, et al. Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis. Support Care Cancer 2022; 30:1015.</a></li><li><a class="nounderline abstract_t">Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011; 9:188.</a></li><li><a class="nounderline abstract_t">Zhang L, Qu X, Teng Y, et al. Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study). J Clin Oncol 2017; 35:3558.</a></li><li><a class="nounderline abstract_t">Todaro B. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw 2012; 10:487.</a></li><li><a class="nounderline abstract_t">Pomeroy M, Fennelly JJ, Towers M. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemother Pharmacol 1986; 17:285.</a></li><li><a class="nounderline abstract_t">Sallan SE, Zinberg NE, Frei E 3rd. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975; 293:795.</a></li><li><a class="nounderline abstract_t">Herman TS, Einhorn LH, Jones SE, et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 1979; 300:1295.</a></li><li><a class="nounderline abstract_t">Grunberg SM, Munsell MF, Morrow PKH, et al. Randomized double-blind evaluation of dronabinol for the prevention of chemotherapy-induced nausea. J Clin Oncol 2012; 30S: ASCO #9061.</a></li><li><a class="nounderline abstract_t">Olver I, Paska W, Depierre A, et al. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. Ann Oncol 1996; 7:945.</a></li><li><a class="nounderline abstract_t">Koo WH, Ang PT. Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol 1996; 7:71.</a></li><li><a class="nounderline abstract_t">Kris MG, Gralla RJ, Tyson LB, et al. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989; 7:108.</a></li><li><a class="nounderline abstract_t">Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 2000; 342:1554.</a></li><li><a class="nounderline abstract_t">Pater JL, Lofters WS, Zee B, et al. The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol 1997; 8:181.</a></li><li><a class="nounderline abstract_t">Hesketh PJ, Sanz-Altamira P, Bushey J, et al. Prospective evaluation of the incidence of nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. J Clin Oncol 2008; 26S: ASCO #9645.</a></li><li><a class="nounderline abstract_t">Hesketh PJ, Sanz-Altamira P, Bushey J, Hesketh AM. Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. Support Care Cancer 2012; 20:1043.</a></li><li><a class="nounderline abstract_t">Fleishman SB, Mahajan D, Rosenwald V, et al. Prevalence of Delayed Nausea and/or Vomiting in Patients Treated With Oxaliplatin-Based Regimens for Colorectal Cancer. J Oncol Pract 2012; 8:136.</a></li><li><a class="nounderline abstract_t">Aapro M, Rugo H, Rossi G, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 2014; 25:1328.</a></li><li><a class="nounderline abstract_t">Roila F, Ruggeri B, Ballatori E, et al. Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study. J Clin Oncol 2014; 32:101.</a></li><li><a class="nounderline abstract_t">Ito Y, Tsuda T, Minatogawa H, et al. Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy. J Clin Oncol 2018; 36:1000.</a></li><li><a class="nounderline abstract_t">Roila F, Ruggeri B, Ballatori E, et al. Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. Ann Oncol 2015; 26:1248.</a></li><li><a class="nounderline abstract_t">Navari RM, Madajewicz S, Anderson N, et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 1995; 13:2408.</a></li><li><a class="nounderline abstract_t">Latreille J, Pater J, Johnston D, et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16:1174.</a></li><li><a class="nounderline abstract_t">Goedhals L, Heron JF, Kleisbauer JP, et al. Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study. Ann Oncol 1998; 9:661.</a></li><li><a class="nounderline abstract_t">Tsukada H, Hirose T, Yokoyama A, Kurita Y. Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis. Eur J Cancer 2001; 37:2398.</a></li><li><a class="nounderline abstract_t">Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 2005; 23:1289.</a></li><li><a class="nounderline abstract_t">Jordan K, Gralla R, Rizzi G, Kashef K. Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens. Support Care Cancer 2016; 24:4617.</a></li><li><a class="nounderline abstract_t">Jordan K, Blättermann L, Hinke A, et al. Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis. Support Care Cancer 2018; 26:21.</a></li><li><a class="nounderline abstract_t">Roscoe JA, Heckler CE, Morrow GR, et al. Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy. J Clin Oncol 2012; 30:3389.</a></li><li><a class="nounderline abstract_t">Wang DS, Hu MT, Wang ZQ, et al. Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial. JAMA Netw Open 2021; 4:e215250.</a></li><li><a class="nounderline abstract_t">Dupuis LL, Roscoe JA, Olver I, et al. 2016 updated MASCC/ESMO consensus recommendations: Anticipatory nausea and vomiting in children and adults receiving chemotherapy. Support Care Cancer 2017; 25:317.</a></li><li><a class="nounderline abstract_t">Morrow GR, Roscoe JA, Kirshner JJ, et al. Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Support Care Cancer 1998; 6:244.</a></li><li><a class="nounderline abstract_t">Roscoe JA, Bushunow P, Morrow GR, et al. Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma. Cancer 2004; 101:2701.</a></li><li><a class="nounderline abstract_t">Chan A, Kim HK, Hsieh RK, et al. Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice--a longitudinal analysis. Support Care Cancer 2015; 23:283.</a></li><li><a class="nounderline abstract_t">Morrow GR, Morrell C. Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 1982; 307:1476.</a></li><li><a class="nounderline abstract_t">Burish TG, Jenkins RA. Effectiveness of biofeedback and relaxation training in reducing the side effects of cancer chemotherapy. Health Psychol 1992; 11:17.</a></li><li><a class="nounderline abstract_t">Fallowfield LJ. Behavioural interventions and psychological aspects of care during chemotherapy. Eur J Cancer 1992; 28A Suppl 1:S39.</a></li><li><a class="nounderline abstract_t">Greenberg DB, Surman OS, Clarke J, Baer L. Alprazolam for phobic nausea and vomiting related to cancer chemotherapy. Cancer Treat Rep 1987; 71:549.</a></li><li><a class="nounderline abstract_t">Razavi D, Delvaux N, Farvacques C, et al. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol 1993; 11:1384.</a></li><li><a class="nounderline abstract_t">Malik IA, Khan WA, Qazilbash M, et al. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol 1995; 18:170.</a></li><li><a class="nounderline abstract_t">Hainsworth JD. The use of ondansetron in patients receiving multiple-day cisplatin regimens. Semin Oncol 1992; 19:48.</a></li><li><a class="nounderline abstract_t">Räth U, Upadhyaya BK, Arechavala E, et al. Role of ondansetron plus dexamethasone in fractionated chemotherapy. Oncology 1993; 50:168.</a></li><li><a class="nounderline abstract_t">Albany C, Brames MJ, Fausel C, et al. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study. J Clin Oncol 2012; 30:3998.</a></li><li><a class="nounderline abstract_t">Adra N, Albany C, Brames MJ, et al. Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study. Support Care Cancer 2016; 24:2837.</a></li><li><a class="nounderline abstract_t">Boccia RV, Gordan LN, Clark G, et al. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 2011; 19:1609.</a></li><li><a class="nounderline abstract_t">Yang LQ, Sun XC, Qin SK, et al. Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study. Chin Clin Oncol 2016; 5:79.</a></li><li><a class="nounderline abstract_t">Kim JE, Hong YS, Lee JL, et al. A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients. Support Care Cancer 2015; 23:1769.</a></li><li><a class="nounderline abstract_t">Raftopoulos H, Cooper W, O'Boyle E, et al. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial. Support Care Cancer 2015; 23:723.</a></li><li><a class="nounderline abstract_t">Boccia R, Cooper W, O'Boyle E. Sustained antiemetic responses with APF530 (sustained-release granisetron) during multiple cycles of emetogenic chemotherapy. J Community Support Oncol 2015; 13:38.</a></li><li><a class="nounderline abstract_t">Mattiuzzi GN, Cortes JE, Blamble DA, et al. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer 2010; 116:5659.</a></li><li><a class="nounderline abstract_t">López-Jiménez J, Martín-Ballesteros E, Sureda A, et al. Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. Haematologica 2006; 91:84.</a></li><li><a class="nounderline abstract_t">Bosi A, Guidi S, Messori A, et al. Ondansetron versus chlorpromazine for preventing emesis in bone marrow transplant recipients: a double-blind randomized study. J Chemother 1993; 5:191.</a></li><li><a class="nounderline abstract_t">Okamoto S, Takahashi S, Tanosaki R, et al. Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study. Bone Marrow Transplant 1996; 17:679.</a></li><li><a class="nounderline abstract_t">Gilbert CJ, Ohly KV, Rosner G, Peters WP. Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation. Cancer 1995; 76:2330.</a></li><li><a class="nounderline abstract_t">Stiff M, Fox-Geiman M, Kiley K, et al. Aprepitant versus placebo plus oral ondansetron and dexamethasone for the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to hematopoietic stem cell transplantation: A prospective, randomized double-blind phase III trial. Blood 2009; 114S: ASH #2267.</a></li><li><a class="nounderline abstract_t">Clemmons AB, Orr J, Andrick B, et al. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial. Biol Blood Marrow Transplant 2018; 24:2065.</a></li><li><a class="nounderline abstract_t">Abbott B, Ippoliti C, Bruton J, et al. Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation. Bone Marrow Transplant 1999; 23:265.</a></li><li><a class="nounderline abstract_t">Barbounis V, Koumakis G, Hatzichristou H, et al. The anti-emetic efficacy of tropisetron plus dexamethasone in patients treated with high-dose chemotherapy and stem cell transplantation. Support Care Cancer 1999; 7:79.</a></li><li><a class="nounderline abstract_t">Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999; 17:2971.</a></li><li><a class="nounderline abstract_t">Yeh SP, Lo WC, Hsieh CY, et al. Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation. Support Care Cancer 2014; 22:1199.</a></li><li><a class="nounderline abstract_t">Stiff PJ, Fox-Geiman MP, Kiley K, et al. Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant 2013; 19:49.</a></li><li><a class="nounderline abstract_t">Schmitt T, Goldschmidt H, Neben K, et al. Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol 2014; 32:3413.</a></li><li><a class="nounderline abstract_t">Einhorn LH, Rapoport B, Navari RM, et al. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 2017; 25:303.</a></li></ol></div><div id="topicVersionRevision">Topic 1151 Version 122.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996130" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Proposal for classifying the acute emetogenicity of cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16314401" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21947834" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Antiemetics: American Society of Clinical Oncology clinical practice guideline update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26527784" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antiemetics: American Society of Clinical Oncology Focused Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27664248" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28759346" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32658626" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Antiemetics: ASCO Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32658626" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Antiemetics: ASCO Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20694798" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18525044" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Chemotherapy-induced nausea and vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7993831" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2169784" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1332737" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9010986" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22993341" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A randomized controlled non-inferiority study comparing the antiemetic effect between intravenous granisetron and oral azasetron based on estimated 5-HT3 receptor occupancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10321418" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emesis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11147601" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9629876" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1386245" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1453211" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8646710" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8674154" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8164029" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9469367" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9552067" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22452942" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24741326" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12921512" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16317736" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20210727" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Other drugs acting on nervous system associated with QT-interval prolongation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18083478" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Dolasetron-induced torsades de pointes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18083478" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Dolasetron-induced torsades de pointes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19261954" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Coronary vasospasm and atrial fibrillation associated with ondansetron therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19261954" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Coronary vasospasm and atrial fibrillation associated with ondansetron therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19261954" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Coronary vasospasm and atrial fibrillation associated with ondansetron therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21773677" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Electrocardiographic findings of palonosetron in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26111957" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14635083" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14504060" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21282670" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19135415" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16766588" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27129842" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27358385" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31217343" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25872578" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25872578" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27176138" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23860530" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26662632" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24746177" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21822913" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25922233" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27795228" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22911671" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11251007" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21383291" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24608196" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24631949" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29092012" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27885469" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34793245" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35045185" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29722791" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31381152" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26272768" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26272769" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26272769" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12844131" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14559886" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12784346" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15837996" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15723220" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11013282" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7990859" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1829757" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1837743" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8120559" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8186174" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31590988" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30280635" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31122901" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9738561" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14966097" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide:.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30246876" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30333194" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27410922" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27410922" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29039073" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32128615" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31838011" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33442782" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34613472" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22024310" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28854065" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22491047" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3017596" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1099449" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/375088" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Randomized double-blind evaluation of dronabinol for the prevention of chemotherapy-induced nausea</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9006746" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9081395" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2642536" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10824073" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9093728" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Prospective evaluation of the incidence of nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21553313" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22942805" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Prevalence of Delayed Nausea and/or Vomiting in Patients Treated With Oxaliplatin-Based Regimens for Colorectal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24603643" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24323030" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29443652" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25743855" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7666101" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9508205" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9681082" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11720834" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15718327" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27334131" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28861627" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22915657" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33835174" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27510314" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : 2016 updated MASCC/ESMO consensus recommendations: Anticipatory nausea and vomiting in children and adults receiving chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9629877" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15517574" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25112561" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice--a longitudinal analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6128673" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1559530" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Effectiveness of biofeedback and relaxation training in reducing the side effects of cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1627407" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Behavioural interventions and psychological aspects of care during chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3567983" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Alprazolam for phobic nausea and vomiting related to cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8315437" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7900711" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1387250" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : The use of ondansetron in patients receiving multiple-day cisplatin regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8459987" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Role of ondansetron plus dexamethasone in fractionated chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22915652" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26838019" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20835873" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28061543" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25465680" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25179689" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25866983" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Sustained antiemetic responses with APF530 (sustained-release granisetron) during multiple cycles of emetogenic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21218459" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16434375" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8371129" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Ondansetron versus chlorpromazine for preventing emesis in bone marrow transplant recipients: a double-blind randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8733681" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8635039" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Aprepitant versus placebo plus oral ondansetron and dexamethasone for the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to hematopoietic stem cell transplantation: A prospective, randomized double-blind phase III trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29906570" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10084258" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Antiemetic efficacy of granisetron plus dexamethasone in bone marrow transplant patients receiving chemotherapy and total body irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10089087" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : The anti-emetic efficacy of tropisetron plus dexamethasone in patients treated with high-dose chemotherapy and stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10561376" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24317849" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22863840" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25225424" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27815710" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
